

# OHE Annual Report to the Charity Commission 2023



**Mireia Jofre-Bonet**  
Graham Cookson



**OCTOBER 2024**

## OHE Annual Report to the Charity Commission 2023

**Mireia Jofre-Bonet**

Office of Health Economics, London

**Graham Cookson**

Office of Health Economics, London

**Please cite this report as:**

OHE, 2024. OHE Annual Report to the Charity Commission 2023, London: Office of Health Economics.

**Corresponding Author:**

Mireia Jofre-Bonet

[mjofre-bonet@ohe.org](mailto:mjofre-bonet@ohe.org)

## Table of Contents

---

OHE Annual Report to the Charity Commission 2023 .....	i
Table of Contents .....	ii
About OHE .....	1
Snapshot of the year 2023.....	2
Administrative information.....	3
Introduction .....	4
Activities undertaken in fulfilment of charitable objects.....	5
Research activity .....	7
Dissemination and Education Activities .....	8
Events .....	8
Summary of impact (beyond scientific citations).....	8
Financial review.....	10
Structure, governance, and management in 2023 .....	13
Epilogue ..	14
APPENDIX: 2023 Research Summary .....	15

## About OHE

### MISSION STATEMENT

Support better health care policies by providing insightful economic and statistical analyses of critical issues.

### HOW WE ARE ORGANISED

The Office of Health Economics (OHE) is a charity with registered charity number 1170829. A senior management team manages OHE and our governance is the responsibility of the Board of Trustees.

The **Board of Trustees** has three sub-committees with advisory roles:

- **Research Committee:** Provides advice and guidance to OHE on its research programme
- **Policy Committee:** Advises OHE on engaging with policymaking and meeting its Charitable Objects
- **Management Committee:** Assists OHE with its operational and business planning.

The Office of Health Economics wholly owns OHE Consulting Limited, which carries out consulting work for third parties. Its profits fund our research and charity activities.

OHE is an **Independent Research Organisation (IRO)**. This status was awarded in 2020 by UK Research and Innovation (UKRI) which – through the seven Research Councils, Innovate UK and Research England – allocates more than £7 billion in research funding, primarily from the Science Budget of the Department for Business, Energy and Industrial Strategy (BEIS).

IRO status recognises the high quality of OHE's independent research, on par with the UK's higher education institutions, and makes us eligible to apply for UKRI funding on the same terms to better fulfil our charitable aims.

### WHO WE ARE, HOW AND WHERE WE WORK






By the end of 2023, the OHE team comprised one Chief Executive Officer; one Deputy Chief Executive Officer, one Chief Research Officer & Head of Education; one Emeritus Director and Visiting Research Fellow, four Directors; two Associate Director; five Senior Principal Economists; three Principal Economists; four Senior Economists; one Business Intelligence; one Business Executive; seven Economists; one Head of Academy and four Administrative Support staff, and two MSc student fellows. Also, in 2023 OHE had nine Honorary Research Fellows.






We emphasise projects that tackle impactful policy and strategic issues with current and future significance. Our work involves stakeholders, clients, and external experts to obtain crucial new policy insights and identify strategies and optimal choices.






Although OHE is based in London, we undertake projects both in the UK and internationally. We work collaboratively with a wide network of academics and other partners worldwide.

## Snapshot of the year 2023

# Our year in numbers...

 <b>RESEARCH</b>	 <b>28 peer-reviewed</b> external publications	 <b>100+ citations</b> for two 2022 OHE journal articles
	 <b>21 blogs</b> authored by OHE	 <b>2x</b> OHE research reports published (14 2023 vs 7 2022)

 <b>EVENTS</b>	 <b>2600+ delegates</b> reached through online and in-person events	 4 profile-raising events including our Annual Lecture
	 15 webinars, masterclasses and seminars	 <b>84 presentations</b> at external conferences

 <b>GLOBAL REACH</b>	 <b>87 countries</b> reached through Educational content	 <b>5,843 X/Twitter</b> and <b>9,926 LinkedIn</b> followers
	 <b>14 global applications</b> for the inaugural Innovation Policy Prize	 <b>89,104</b> website users

## Administrative information

### Trustees and Directors

#### By the end of 2023 :

Anita Charlesworth , *The Health Foundation Chair*  
Richard Torbett , *(APBI) Trustee*  
Werner Brouwer , *ESHPM (OHE) Trustee (appointed 31st March 2022)*  
Patrick Holmes , *Pfizer (ABPI) Trustee (appointed 31st January 2022)*  
Margaret Kyle , *Mines ParisTech (OHE) (appointed 14th January 2022)*  
Paul Catchpole , *(ABPI) Trustee (appointed 4th October 2023)*  
Thomas Allvin, *EFPIA (appointed 23<sup>rd</sup> February 2023)*  
*Other:*  
Susan Rienow , *Pfizer (ABPI) (resigned 4th October 2023)*

#### By the end of 2022

Anita Charlesworth    The Health Foundation Chair  
Richard Torbett        (APBI) Trustee  
Werner Brouwer        ESHPM (OHE) Trustee (appointed 31<sup>st</sup> March 2022)  
Patrick Holmes         Pfizer (ABPI) Trustee (appointed 31<sup>st</sup> January 2022)  
Margaret Kyle         Mines ParisTech (OHE) (appointed 14<sup>th</sup> January 2022)  
Susan Rienow         Pfizer (ABPI) (appointed 5<sup>th</sup> October 2022)

#### Other:

Mr U Bose                (Boehringer Ingelheim) Trustee (resigned 31<sup>st</sup> October 2022)  
Prof B Jonsson         Trustee (resigned 14<sup>th</sup> January 2022)  
Prof M Drummond      Trustee (resigned 14<sup>th</sup> January 2022)  
Mr B S Sahota          Trustee (resigned 5<sup>th</sup> October 2022)

### Registered Office

2nd Floor Goldings House, Hay's Galleria, 2  
Hay's Lane, London, SE1 2HB  
**Charity number:** 1170829  
**Company number:** 09848965

### Auditor

#### BDO LLP

Statutory Auditor & Chartered Accountants  
2 City Place  
Beehive Ring Road  
Gatwick  
West Sussex RH6 0PA

### Bankers

#### National Westminster Bank Plc

PO Box 113  
Cavell House  
2A Charing Cross Road, London

### Senior Management

#### Chief Executive Officer

Prof Graham Cookson

#### Deputy Chief Executive Officer

Prof Lotte Steuten

#### Chief Research Officer and Head of

#### Education

Prof Mireia Jofre-Bonet

#### Directors:

Charlotte Ashton  
Martina Garau  
Chris Skedgel  
Tim Watson

#### Associate Directors:

Grace Hampson  
Amanda Cole

## Introduction

This is the seventh submission to the Charity Commission for England and Wales since our registration as a charity in December 2016. The **2023 Charity Report** includes this document, which outlines our activities and provides the necessary financial details. The Appendix, titled Research Summary of 2023 for the Charity Report, is based on the report submitted to the Research Committee in February 2024 and details OHE's research activities for 2023.

The 2023 Charity Report once again demonstrates OHE's dedication to its charitable objectives of educating the public, healthcare payers, and policymakers on health economics and healthcare policy. Additionally, OHE employs health economics methods to generate evidence-based health policy and management, thereby contributing to a more efficient and effective healthcare system.

Beyond OHE's charitable objects at OHE, we also support:

- The advancement of evidence-based health care policy by engaging in research on the economics of health, health care systems and the life sciences industry
- Research for the effective and efficient use of health care resources by advancing the use of economic approaches to support decision making; and
- Decision-making and awareness of health care policy issues by promoting debate and disseminating relevant health economics research.<sup>1</sup>

The Charity Report for the year 2023 is organised as follows: the first section summarises the activities undertaken in fulfilment of OHE's charitable objects; the second provides Financial review, followed by a description of the Structure, governance, and management in 2023; the final section, the Epilogue, concludes.

---

<sup>1</sup> *The term health economics shall mean the application of economic theory, models and empirical techniques to the analysis of decision making by people, health care providers and governments with respect to health and health care.*



## Activities undertaken in fulfilment of charitable objects

In this report aims we provide an account of OHE's performance in its **Charitable Purpose** and its **Impact** as defined below:

**Charitable Purpose** – Deliver on OHE Charitable Objects and maintain OHE social purpose, where the charitable objects are:

To advance the education of the public in general/healthcare payers/policymakers (particularly patients and healthcare professionals) about health economics and healthcare policy.

Activities in furtherance of this will include, but not exclusively:

- Promotion of evidence-based health care policy by carrying out research on the economics of health, health care systems and the life sciences industry,
- promotion of effective and efficient use of health care resources by advancing the use of economic approaches to support decision making; and
- facilitating decision-making and awareness of health care policy issues by encouraging debate and disseminating relevant health economics research.

**Impact** – Have a measurable impact on health care policy and decision-making.

As these two aims overlap, i.e., the impact is embedded in the Charitable Objects, we report our activity as follows:

1. **Research Activity** that promotes evidence-based healthcare policy and the effective and efficient use of healthcare resources
2. **Dissemination and Education Activities** that advance the education of the public/general health care payers/policymakers about health economics and healthcare policy
3. **Events** that encourage debate facilitate decision-making and increase awareness of health care policy issues
4. **Impact** summarised as a list indicative of the resonance of OHE's research or activities in decision-making in health care

The snapshot of activity and output in the introductory pages illustrates visually the breadth of OHE's research activity, events, dissemination, and education activities that encourage exchanging ideas and increasing awareness of health care policy issues, as of December 2023. Below, we provide a table matching some of these activities to two of our charity objects.

Table: OHE activities and Charity Objects

	Promotion of evidence-based health care policy, by <b>carrying out research on the economics of health, health care systems and the life sciences industry;</b>	Facilitation of decision making and awareness of health care policy issues, by <b>encouraging debate and dissemination</b> of relevant health economics research.
Impact and Evidence	<b>8 OHE publications (reports)</b>	<b>OHE Innovation Policy Prize</b>
	<b>28 Peer-reviewed journal publications and 1 book chapter</b>	<b>2 x Masterclasses</b> • Severity in Value Assessment: From Principle to Practice • Multi-Indication Therapies
	<b>20 Blog posts</b>	
	<b>84 Presentations at conferences</b>	
		<b>Lunchtime Seminars</b>
		• 'The Value of a QALY Towards the End of Life and its Determinants'
		• 'An Economic Evaluation of Next-Generation Sequencing Testing for Non-small Cell Lung Cancer in England'
		• 'Identification of the Health Benefits with the Emission Trading Scheme in Europe'
		<b>Annual Lecture</b>
		• The ECO-nomics of Health in a Shifting Climate: Fostering Sustainable Livelihoods and a Greener Future
		<b>4 x Webinars (non-sponsored)</b>
		• The Value of Vaccines and Taskforces
	• Considering Carer Burden in HTA: 3 -part Webinar	
	• EVIA programme: Valuing Vaccines: The Economics of Vaccines and Immunisation	
	• Reimagining Prevention for a Healthier, More Prosperous Society	
	<b>4x sponsored Webinars</b>	
	• Evaluating Multiple Myeloma Therapies: Challenges to Value Demonstration and Value Recognition	
	• Supporting Sustainability in the Era of Green Pharmaceuticals	
	• Partnerships for Health System Innovation and Improvement	
	• Lung Cancer's Biggest Test: How Can We Mobilise NGS Testing to Transform Lung Cancer Care	

## Research activity

OHE's research activity in 2023 was extensive and diverse. Our grant-funded, contract, and core research projects translated into an remarkable **publication track record**. In 2023, we published a total of 28 peer-reviewed journal articles and 9 OHE reports, compared to 27 in the equivalent period last year.

We made progress in achieving publications funded through our **core research grant**. Core-funded research projects resulted in 2 peer-reviewed publications in 2023, compared to 0 in 2022, with 3 further submissions by the end of the year. Regarding the impact of our publications, we tracked citations for OHE journal articles published since 2018. As expected, citations are increasing with the age of publications. In the five years between 2018 and 2022, we published 73 articles with 10 citations or more, of which 18 have received more than 50 citations and 8 have received more than 100. As would be expected, older publications have received greater numbers of citations to date.

In terms of downloads, in 2023, OHE undertook a full website relaunch. Changes to our analytics, and minor disruptions during the transition period, can explain the small decrease in the number of website visitors and downloads (see Appendix for more details).

## Research awards from prestigious funders and funded research projects

We increased research grant funding for OHE research. Live research grant-funded projects at the end of the year were worth a combined value of £2.3 million. The total value of research grants won in 2023 was £1.19 million but by the end of 2023 there were £1.7 million in the pipeline. We capitalised on our success in securing the EU HORIZON HI-PRIX project and have consequently been approached by various consortia submitting other EU HORIZON grant applications as well as two to the NIHR. On the other hand, we reinforced our relationship with the African Institute of Inclusive Growth and submitted two research grant applications with them.

OHE was also awarded a UKRI Knowledge Transfer Partnership grant in association with the Computer Sciences Department of City, University of London, to incorporate Artificial Intelligence into our Health Technology Assessment research offer. This collaboration with City, University of London, might have an impact on OHE's future research.

For an overview of our research income for 2023 please refer to our research summary for 2023 in the Appendix.

## Dissemination and Education Activities

As described in the research summary,, in 2023, OHE continued its commitment to dissemination and education activities through a combination of virtual and face-to-face events.

We convened a significant number of research events: 3 roundtables; 3 lunchtime seminars; 8 webinars; 2 workshops, and 4 events aimed at external audiences. OHE colleagues gave 84 external presentations in 2023, more than thrice the number of 2022.

In 2023, we also launched the **OHE Academy** ([Academy - OHE](#)), a platform that furthers our charitable mission by providing education | health economics suitable for learners at all stages of their journey and disseminating evidence-based health policy making.

Additionally, this year OHE allocated a substantial amount of pro-bono effort to update the 2014 edition of [The Dictionary of Health Economics, Third Edition \(e-elgar.com\)](#), originally written by Tony Culyer.

## Events

OHE's has continued to organise events and present our research in different formats. Events encourage debate and facilitate decision-making, meeting another of our charity objects.

Our webinar activities in particular increased notably compared to 2022. Four of our webinars were funded, and as such this represents an important opportunity for diversifying OHE's sources of research income, whilst simultaneously allowing us to disseminate our research to new audiences. The majority of our webinars received over 100 registrations and the overall number of delegates reached exceeded 2,200. OHE are committed to incorporating more diversity in webinar panels as well as reaching a more global audience, reaching 81 countries In 2023.

Our main profile-raising event, the 2023 Annual Lecture, brought Professor Elizabeth Robinson to the stage to reframe the economics of health and healthcare in a shifting climate. This underscores OHE's dedication to combining health economics with environmental economics to contribute to the alleviation of the healthcare/ climate crisis.

## Summary of impact (beyond scientific citations)

In this section we aim to provide an idea of the impact of OHE research that goes beyond the number of publications and/or scientific citations summarising a few examples.. In the research summary at the end of this document, we provide a more detailed selection of impactful outputs using other metrics, e.g., summary statistics of the downloads and visits to our website, as well as a list of our advisory roles and external presentations.

### Selection of Impactful Research Outputs

As detailed in the research summary in the appendix, in 2023, OHE's research had impact across an impressive range and depth of topics. There are at least four OHE pieces of work that have salient effects in terms of digital imprint and broader coverage: the **IRA Reduction Act** on the USA pharmaceutical regulation reform that will influence extraordinarily the pharmaceutical R&D landscape not only in the US but globally; the high profile projects on

**Health Technology Assessment bodies** (from 'NICE enough' to 'Around the world in HTAs'); the work on **sustainability**; and, last but not least, several leading pieces of work on **Antibiotic Microbial Resistance** that include three reports related to the NICE/NHS England AMR Pilot.

### Impact through pro bono activities

The research summary for 2023 in the Appendix shows that OHE staff continue to engage in a wide variety of *pro bono* activities, including membership on advisory panels, boards and committees and eleven associations with universities. Pro bono activities also include prestigious think tanks, participation on advisory boards, serving on committees, supervising student placements, examining doctoral research theses, and undertaking reviews.

## Financial review

### Financial structure

In 2023, OHE remained an organisation undertaking research and related activities according to its charitable objects and status of independent research organisation.

OHE owns the sole share in *OHE Consulting Limited* with the purpose of enabling OHE to:

- **employ** a larger staff team than would be possible using research income alone
- allow staff to **gain knowledge**, skills and experience undertaking consulting projects that can be carried across into research and research-related projects
- Most importantly, **invest** the profits generated from consultancy work as Gift Aided to OHE, to fund OHE's activities in 2023.

In 2023, OHE employed an average of thirty-eight staff of which 31 were researchers. Research staff are organised in four research themes as deployed in the diagram below.

In July of 2023, OHE implemented a structural reorganisation of its staff. Besides the four research themes, an OHE Graduate School and an OHE Academy were launched under the supervision of the Chief Research Officer and Head of Education. Additionally, a Director of Marketing and Communications and a Director of External Affairs were hired.



## Financial performance in 2023

The financial statements of OHE comply with the Charities Act 2011, the Companies Act 2006, the Memorandum and Articles of Association, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts following The Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) ("Charities SORP FRS 102").

OHE's consolidated turnover (i.e., combining both OHE and OHE Consulting Limited) in 2023 was **£4.46m**. The expenditure totalled **£4.59m**, leaving a net income of -£130,451.

Of the £4.59m expenditure, staff costs in 2023 amounted to **£3.18m**, i.e., 67%.

Support services for the consolidated businesses accounted for **£0.36m**.

The consolidated accounts for OHE are included as an Annex to this report.

## Sources of funding

The sources of funding for OHE are summarised below. The financial reports attached provide more details about OHE income and expenditure.

The consolidated income of £4.46m comprises:

	£000
Donations – research grants	211
Income from charitable (research) activities	697
Interest	9.4
Total research income	919*
OHE Consulting Income	3,545
Total Income	4,464

\*£919 due to rounding up.

Donations are from the ABPI and are for two distinct purposes:

	£000
Support for core research activities	200
Grant towards financing of support activities	368
Total	568


\*Income from charitable (research) activities came from several sources. Major research projects and funders included: European Union grants, ALAN, Health Foundation, the Cancer Research UK, EuroQol Research Foundation.



## Structure, governance, and management in 2023

Figure 1 below shows the OHE governance structure at the end of 2023. At the top is the **OHE Board of Trustees**. The Board is supported by the **Policy Committee** and the **Research Committee**. The Policy Committee advises OHE on policy impact, ensuring OHE meets the Charitable Object of supporting evidence-based decision-making. OHE has informed healthcare and pharmaceutical decision-makers and payers for decades with independent, academically strong research. The Research Committee guides OHE on research methods, oversees the core research grant program, and ensures the quality and independence of OHE's research.

Figure 1: Organigram by the end of 2023



## Epilogue

In sum, the year 2023 has furthered OHE's path as a charity, not least by launching the OHE Academy, an educational platform in health economics, and updating the Dictionary of Health Economics.

The strong results in terms of research outcomes reinforce the positive trend that OHE has experienced in the last five years as an organisation committed to disseminating evidence-based decision-making in health policy.

In 2024, OHE have kept the pace, and we expect to continue achieving our charitable objectives by continuing to support evidence-based research in health economics and our educational and dissemination activities.

## APPENDIX: 2023 Research Summary

### Research Programme Output

In the following sections, we provide a list and some insights into 2023 research outputs, including research funded grant projects, publications, core-funded projects and OHE organised events.

### Research grants and projects

The number and amount of live research grant funded projects in 2023 is higher than last year and amounts to £2.3 million. See below:

The pipeline and the research grant applications lost show that the year 2023 has been a very active year for collaboration with other European institutions applying to European HORIZON research grant calls. Although so far, the research funded grants won in 2023 amount £1.19 million.

### 2023 Live Research Grant Funded Projects

Funder	Project Title	Theme	Year won	Project Budget
Euroqol Research Foundation	Estimating an EQ-5D –Y-3L value set in the UK	MVO	2023	7,650.00
Curta, Inc	Biosimilar Market Dynamics: A Review and Simulation Model	Eol	2023	24,252.00
The Vegan Society	Burden of non-vegan diets	POIHS	2023	10,000.00
Epilepsy Society	Impact of ADHD and Autism in Epilepsy	VADM	2023	29,500.00
Acute Leukemia Advocates Network	Patient preferences for Leukemia treatments: UK/US/EU4 R/R/all phases	MVO	2023	105,117.00
Acute Leukemia Advocates Network	Patient preferences for Leukemia treatments: UK/US/EU4 1L all phases	MVO	2023	210,477.00
Acute Leukemia Advocates Network	Acute Leukemia carer preference study	MVO	2023	149,876.00
Acute Leukemia Advocates Network	Patient preferences for Leukemia treatments: UK R/R phases 5-6	MVO	2023	73,789.00
Taiwan HTA workshop	Novartis Inc	EOI	2023	4,000.00
High Flow Therapy UK	High Flow Therapy Post AECOPD	VADM	2023	71,159.00
Oncology TPPs	Cancer Research UK (CRUK)	EOI	2023	66,406.00
National University of Singapore	Sustainable Financing Models to Support the Development of and Access to Novel Antibiotics in Singapore	EOI	2023	12,807.00
European Commission	EU HORIZON 2022 : HI-PRIX Project	EOI	2023	354,263.00
<b>Projects won in 2023</b>				<b>1.119.296.00</b>
EuroQol Research Foundation	Extension of Development and testing of a hearing bolt-on	MVO	2022	11,611
Acute Leukemia Advocates Network	Patient preferences for leukemia treatments: US/EU4 R/R all phases	MVO	2022	105,117
Pfizer Inc	Educational Course Vaccine Economics	VADM	2022	255,429
EuroQol Research Foundation	Estimating an EQ-5D-Y-3L value set in the United Kingdom	MVO	2022	7,650

EuroQol Research Foundation	Exploring the use of the OPUF tool for valuing EQ-5D-Y-3L	MVO	2022	63,310
National University of Singapore	Sustainable financing models to support Development of and access to novel antibiotics in Singapore	EOI	2022	12,807
High Flow Therapy UK	High Flow Therapy Post AECOPD	VADM	2022	74,159
EuroQol Research Foundation	Development and testing of a hearing bolt-on	MVO	2021	77,456
Acute Leukemia Advocates Network	Patient preferences for leukemia treatments: UK R/R phases 1-4	MVO	2021	146,099
Parkinson's UK	PwP Mindfulness app	VADM	2021	15,318
The Health Foundation	Efficiency and Labour Productivity in Primary Care	POIHS	2021	410,325
EuroQol Research Foundation	Experience TTO	MVO	2019	3,200
EuroQol Research Foundation	EQ-5D Bolt-on Development	MVO	2018	57,700
<b>Projects won prior to 2023</b>				<b>1,240,181.00</b>
<b>Total Live</b>				<b>2,359,477.00</b>

## 2023 Pipeline and Lost Grant Funded Projects

Project Title	Funder	Research Theme	Status	Budget Total <sup>2</sup>
A gamified approach to combat vaccine hesitancy	UKRI	POIHS	Lost	77,225.00
AI4Kidney	European Commission	VADM	Lost	300,000.00
Review of Equity Reporting Lists	Bristol Myers Squibb	VADM	Lost	160,805.00
Climate change & health	Wellcome Trust	Other	Lost	682,802.00
Primary care metrics	NHS England	POIHS	Lost	53,000.00
Development and Evaluation of a Refined Version of the OPUF Approach	EuroQol Research Foundation	MVO	Lost	6,440.00
NIHR COPD Screening trial	National Institute for Health Research NIHR	VADM	Lost	99,777.00
PACT-AM app Care-partner of PwP	Medical Research Council	MVO	Lost	21,297.00
METEOR	European Commission	VADM	Lost	284,563.00
Patient preferences for 1L leukemia treatments	Acute Leukemia Advocates Network	MVO	Lost	209,782.00
WorkHO Horizon Hlth 2023	European Commission	POIHS	Lost	196,785.00
<b>Total lost 2023</b>				<b>2,092,476.00</b>
BIONICS	European Commission	EOI	Potential	250,000.00
CML Patient preference study	CML Advocates Network	MVO	Potential	395,551.00
Cognition bolt-on Hong Kong	EuroQol Research Foundation	MVO	Potential	2,254.00
Decarbonising H&SC	UKRI	POIHS	Potential	0
HEU FTD liquid biopsy	European Commission	VADM	Potential	350,000.00
Memory Tracks evaluation	National Institute for Health Research	VADM	Potential	50,000.00
ModEx	National Institute for Health Research	VADM	Potential	10,000.00
NIHR i4i application	National Institute for Health Research	VADM	Potential	81,870.00
OPUF bolt-on valuation	EuroQol Research Foundation	MVO	Potential	0

<sup>2</sup> These figures do include the total budget of the application, not necessarily what OHE would receive.

Sign language extension of Development and testing of a hearing bolt-on	EuroQol Research Foundation	MVO	Potential	34,689.00
NIHR Global LMICs Partnership	National Institute for HHealth Research (NIHR)	POIHS	Potential	200,000.00
Bill & Melinda Gates Advance Women's Health Innovation	Bill and Melinda Gates	POIHS	Potential	150,000.00
Adult social care technology evaluation	University of Hertfordshire	VADM	Potential	34,517.00
Belberry Seville	MSD Switzerland	VADM	Potential	172,928.00
<b>Total Pipeline</b>				<b>1,731,809.00</b>

## Publications

We present our publications in three main groups: publications in external peer-reviewed journals; publications on OHE's website (peer-reviewed by the OHE reviewing process); OHE reports; books and chapters; and working papers in external institutions.

### External peer-reviewed Journal articles (January to September 2023)

For external peer-reviewed journal articles, we provide information on the sources of financial support, number of citations, SJR indicator and ABS journal ranking.

NO	JOURNAL REFERENCE	Sources of financial support	NUMBER OF CITATIONS (AS OF 1 OCT 2023) <sup>1</sup>	SJR Indicator (2022) <sup>2</sup>	ABS JOURNAL RANKING (2021) <sup>3</sup>
1	Laliotis, I., Shaikh, M., Stavropoulou, C. and Kourouklis, D., 2023. Retirement and Household Expenditure in Turbulent Times. Journal of Family and Economic Issues. <a href="https://link.springer.com/article/10.1007/s10834-022-09884-7">https://link.springer.com/article/10.1007/s10834-022-09884-7</a> DOI: 10.1007/s10834-022-09884-7	Unfunded	0	0.511	2

NO	JOURNAL REFERENCE	Sources of financial support	NUMBER OF CITATIONS (AS OF 1 OCT 2023) <sup>1</sup>	SJR Indicator (2022) <sup>2</sup>	ABS JOURNAL RANKING (2021) <sup>3</sup>
2	Di Fusco, M.; Mendes, D.; Steuten, L.; Bloom, D.E.; Drummond, M.; Hauck, K.; Pearson-Stuttard, J.; Power, R.; Salisbury, D.; Towse, A.; Roiz, J.; Szabo, G.; Yang, J.; Marczell, K. The Societal Value of Vaccines: Expert-Based Conceptual Framework and Methods Using COVID-19 Vaccines as a Case Study. <i>Vaccines</i> 2023, 11, 234. <a href="https://doi.org/10.3390/vaccines11020234">https://doi.org/10.3390/vaccines11020234</a> <a href="https://www.mdpi.com/2076-393X/11/2/234">https://www.mdpi.com/2076-393X/11/2/234</a>	Unfunded	4	1.655	N/A
3	Zamora, B. and Towse, A., 2023. The Cost-Per-QALY Threshold In England: Addressing Structural Uncertainty In The Estimates. <i>Frontiers in Health Services</i> . <a href="https://www.frontiersin.org/articles/10.3389/frhs.2022.936774">https://www.frontiersin.org/articles/10.3389/frhs.2022.936774</a> DOI: 10.3389/frhs.2022.936774	ABPI	0	N/A	N/A
4	Yaman, F., Cubí-Mollá, P. and Ungureanu, S., 2023. Which Decision Theory Describes Life Satisfaction Best? Evidence from Annual Panel Data. <i>Journal of Happiness Studies</i> <a href="https://link.springer.com/article/10.1007/s10902-023-00627-5">https://link.springer.com/article/10.1007/s10902-023-00627-5</a> DOI: 10.1007/s10902-023-00627-5	Core funded	2	1.528	1
5	Skedgel, C., Cubi-Molla, P., Mott, D., Gameiro, S., Boivin, J., Al-Janabi, H., Brazier, J., Markert, M., Andersson, F. L., Jofre-Bonet, M., 2023. Unmet Parenthood Goals, Health-Related Quality of Life and Apparent Irrationality: Understanding the Value of Treatments for Infertility. <i>PharmacoEconomics – Open</i> . <a href="https://link.springer.com/article/10.1007/s41669-023-00402-5">https://link.springer.com/article/10.1007/s41669-023-00402-5</a> DOI: 10.1007/s41669-023-00402-5	Ferring P21B	0	1.389	2
6	Banal-Estañol, A., Jofre-Bonet, M., Lor, G., Maynou, L., Tumminello, M., Vassallo, P., Performance-based research funding: Evidence from the largest natural experiment worldwide, <i>Research Policy</i> , Volume 52, Issue 6, 2023, 104780, ISSN 0048-7333, <a href="https://doi.org/10.1016/j.respol.2023.104780">https://doi.org/10.1016/j.respol.2023.104780</a> .	Unfunded	3	3.634	4*
7	Berdud, M., Wallin-Bernhardsson, N., Zamora, B., Lindgren, P., & Towse, A. (2023). The Allocation of the Economic Value of Second-Generation Antipsychotics Over the Product Life Cycle: The Case of Risperidone in Sweden and the United Kingdom. <i>Value in Health</i> , 26(3), 328-335. <a href="https://www.sciencedirect.com/science/article/abs/pii/S1098301523000402">https://www.sciencedirect.com/science/article/abs/pii/S1098301523000402</a> DOI: 10.1016/j.jval.2022.11.022	Contract funded (Johnson & Johnson)	2	1.414	N/A



NO	JOURNAL REFERENCE	Sources of financial support	NUMBER OF CITATIONS (AS OF 1 OCT 2023) <sup>1</sup>	SJR Indicator (2022) <sup>2</sup>	ABS JOURNAL RANKING (2021) <sup>3</sup>
8	Newall AT, Beutels P, Kis Z, Towse A, Jit M (2023). Placing a value on increased flexible vaccine manufacturing capacity for future pandemics. <i>Vaccine</i> . 2023 Mar 2:S0264-410X(23)00219-0. doi: 10.1016/j.vaccine.2023.02.065. Epub ahead of print. PMID: 36870878; PMCID: PMC9978930. <a href="https://www.sciencedirect.com/science/article/pii/S0264410X23002190?via%3Dihub">https://www.sciencedirect.com/science/article/pii/S0264410X23002190?via%3Dihub</a> doi: 10.1016/j.vaccine.2023.02.065 PMID: 36870878		0	1.493	N/A
9	Jofre-Bonet M, Kamara J, Mesnard A (2023) Corruption and informal sector households' participation in health insurance in Sierra Leone. <i>PLoS ONE</i> 18(4): e0281724. <a href="https://doi.org/10.1371/journal.pone.0281724">https://doi.org/ 10.1371/journal.pone.0281724</a>	Unfunded	3	0.855	N/A
10	Ramsey, S. D., Bansal, A., Li, L., O'Donnell, P. V., Fuchs, E. J., Brunstein, C. G., Eapen, M., Thao, V., Roth, J. A., & Steuten, L. (2023). Cost-Effectiveness of Unrelated Umbilical Cord Blood vs. HLA Haploidentical Related Bone Marrow Transplant: Evidence from BMT CTN 1101. <i>Transplantation and cellular therapy</i> , S2666-6367(23)01257-5. <a href="https://www.sciencedirect.com/science/article/abs/pii/S2666636723012575?via%3Dihub">https://www.sciencedirect.com/science/article/abs/pii/S2666636723012575?via%3Dihub</a> <a href="https://doi.org/10.1016/j.jtct.2023.04.017">https://doi.org/10.1016/j.jtct.2023.04.017</a> PMID: 37120135	Grant funded (NIH National Heart, Lung, and Blood Institute)	1	1.814	N/A
11	Neri, M., Brassel, S., Schirmmacher, H., Mendes, D., Vyse, A., Steuten, L. and Hamson, E., 2023. Vaccine-Preventable Hospitalisations from Seasonal Respiratory Diseases: What Is Their True Value?. <i>Vaccines</i> , 11(5), p.945. <a href="https://www.mdpi.com/2076-393X/11/5/945">https://www.mdpi.com/2076-393X/11/5/945</a> DOI: 10.3390/vaccines11050945	Contract funded (Pfizer)	2	1.655	N/A
12	Shafrin J., Lakdawalla D., Doshi J.A., Garrison L.P., Malani A., Neumann P.J., Phelps C.E., Towse A., and Willke R.J. (2023). A Strategy For Value-Based Drug Pricing Under The Inflation Reduction Act. <i>Health Affairs Forefront</i> , May 4, 2023. DOI: 10.1377/forefront.20230503.153705 <a href="https://www.healthaffairs.org/content/forefront/strategy-value-based-drug-pricing-under-inflation-reduction-act">https://www.healthaffairs.org/content/forefront/strategy-value-based-drug-pricing-under-inflation-reduction-act</a> 10.1377/forefront.20230503.153705	Core funded	5	N/A	N/A

NO	JOURNAL REFERENCE	Sources of financial support	NUMBER OF CITATIONS (AS OF 1 OCT 2023) <sup>1</sup>	SJR Indicator (2022) <sup>2</sup>	ABS JOURNAL RANKING (2021) <sup>3</sup>
13	Firth, I., Hitch, J., Henderson, N. and Cookson, G., Moving towards a More Environmentally Sustainable Pharmaceutical Industry: Recommendations for Industry and the Transition to Green HTA. Expert Review of Pharmacoeconomics & Outcomes Research. <a href="https://www.tandfonline.com/doi/full/10.1080/14737167.2023.2214730">https://www.tandfonline.com/doi/full/10.1080/14737167.2023.2214730</a> DOI: 10.1080/14737167.2023.2214730 PubMed PMID: 37191398	Core funded	2	0.596	N/A
14	Garrison L.P. and Towse A. The IRA's Request For Product-Specific R&D Cost Information: Short-Sighted And Irrelevant. Health Affairs Forefront, June 5, 2023. DOI: 10.1377/forefront.20230602.550273. Available at <a href="https://www.healthaffairs.org/content/forefront/ira-s-request-product-specific-r-d-cost-information-short-sighted-and-irrelevant">https://www.healthaffairs.org/content/forefront/ira-s-request-product-specific-r-d-cost-information-short-sighted-and-irrelevant</a> DOI: 10.1377/forefront.20230602.550273	Core funded	3	N/A	N/A
15	Neri M, Brassel S, Akerjord S, Charos A, Schley K, Steuten L, Recognising the broader value of meningococcal vaccination: a matter of evidence, ability or willingness?, Value in Health (2023), doi: <a href="https://doi.org/10.1016/j.jval.2023.06.011">https://doi.org/10.1016/j.jval.2023.06.011</a> .	Contract funded (Pfizer)	0	1.414	N/A
16	Hafidz F and Sampson C (2023) Editorial: Insights in cost and resource allocation: 2022. Front. Health Serv. 3:1254318. doi: <a href="https://doi.org/10.3389/frhs.2023.1254318">10.3389/frhs.2023.1254318</a>	Unfunded	0	N/A	N/A
17	Berdud M, Ferraro J, Towse A. 2023. A theory on ICER pricing and optimal levels of cost-effectiveness thresholds: a bargaining approach. Frontiers in Health Services Volume 3	Core Funded	5	N/A	N/A
18	Mott, D. J., Schirmacher, H., Al-Janabi, H., Guest, S., Pennington, B., Scheuer, N., Shah, K. K., & Skedgel, C. (2023). Modelling Spillover Effects on Informal Carers: The Carer QALY Trap. Pharmacoeconomics. <a href="https://doi.org/10.1007/s40273-023-01316-0">https://doi.org/10.1007/s40273-023-01316-0</a> <a href="https://link.springer.com/article/10.1007/s40273-023-01316-0">https://link.springer.com/article/10.1007/s40273-023-01316-0</a> DOI: 10.1007/s40273-023-01316-0 PMID: 37659032	Grant Funded	1	1.389	2
19	Brassel, S., Al Taie, A. and Steuten, L., 2023. Value assessment of antimicrobials using the STEDI framework – How steady is the outcome?. Health Policy, 136, p.104892. <a href="https://www.sciencedirect.com/science/article/pii/S016885102300177X">https://www.sciencedirect.com/science/article/pii/S016885102300177X</a> <a href="https://doi.org/10.1016/j.healthpol.2023.104892">https://doi.org/10.1016/j.healthpol.2023.104892</a> PMID: 37632993	Contract Funded (Pfizer)	1	1.062	2

NO	JOURNAL REFERENCE	Sources of financial support	NUMBER OF CITATIONS (AS OF 1 OCT 2023) <sup>1</sup>	SJR Indicator (2022) <sup>2</sup>	ABS JOURNAL RANKING (2021) <sup>3</sup>
20	Hayes, H., Meacock, R., Stokes, J. and Sutton, M., 2023. How do family doctors respond to reduced waiting times for cancer diagnosis in secondary care?. The European Journal of Health Economics, pp.1-16. <a href="https://link.springer.com/article/10.1007/s10198-023-01626-2">https://link.springer.com/article/10.1007/s10198-023-01626-2</a> <a href="https://doi.org/10.1007/s10198-023-01626-2">https://doi.org/10.1007/s10198-023-01626-2</a>	Core funded	0	1.042	2
21	Jakubczyk, M., Schneider, P., Lipman S.A., and Sampson, C., 2023. This dead or that dead: framing effects in the evaluation of health states. Value in Health. <a href="https://www.valueinhealthjournal.com/article/S1098-3015(23)06155-7/fulltext">https://www.valueinhealthjournal.com/article/S1098-3015(23)06155-7/fulltext</a> 10.1016/j.jval.2023.10.009 PMID 37913922	Grant funded research (EuroQoL Research Foundation)	0	1.414	N/A
22	Harding S, Alshukri A, Appelbe D, Broadbent D, Burgess P, Byrne P,... Sampson, C. et al. Individualised variable-interval risk-based screening in diabetic retinopathy: the ISDR research programme including RCT. Programme Grants Appl Res 2023;11(6) <a href="https://www.journalslibrary.nihr.ac.uk/pgfar/HRFA3155">https://www.journalslibrary.nihr.ac.uk/pgfar/HRFA3155</a> (I'm in the 'et al.')	n/a old project	0	N/A	N/A
23	Gordon, J., Gheorghe, M., Harrison, C. et al. Estimating the Treatment and Prophylactic Economic Value of New Antimicrobials in Managing Antibiotic Resistance and Serious Infections for Common Pathogens in the USA: A Population Modelling Study. PharmacoEconomics (2023). <a href="https://doi.org/10.1007/s40273-023-01337-9">https://doi.org/10.1007/s40273-023-01337-9</a>	Core funded	0	1.389	2
24	Paulden, M., Sampson, C., O'Mahony, J.F., Spackman, E., McCabe, C., Round, J. and Snowsill, T. 2023. Logical inconsistencies in the health years in total and equal value of life years gained. Value in Health. <a href="https://doi.org/10.1016/j.jval.2023.11.009">https://doi.org/10.1016/j.jval.2023.11.009</a>	Unfunded	0	1.414	N/A
25	Hampson, G and Steuten, L. 2023. Netflix and pill: is there a role for volume delinked subscription-style payments beyond antimicrobials? Expert Review of Pharmacoeconomics & Outcomes Research, DOI: 10.1080/14737167.2023.2271171	Unfunded	0	0.596	N/A
26	Sampson, C., Leech, A., and Garcia-Lorenzo, B. 2023. Opportunity costs in health care: cost-effectiveness thresholds and beyond. Frontiers in Health Services <a href="https://doi.org/10.3389/frhs.2023.1293592">https://doi.org/10.3389/frhs.2023.1293592</a>	Unfunded	1	N/A	N/A

NO	JOURNAL REFERENCE	Sources of financial support	NUMBER OF CITATIONS (AS OF 1 OCT 2023) <sup>1</sup>	SJR Indicator (2022) <sup>2</sup>	ABS JOURNAL RANKING (2021) <sup>3</sup>
27	Wahlberg K, Winblad B, Cole A, Herring WL, Ramsberg J, et al. People get ready! A new generation of Alzheimer's therapies may require new ways to deliver and pay for healthcare. J Intern Med. 2023; 00: 1–1	Grant funded (paid for my travel to attend and contribute to workshop). Think Tank; Innovative Payment Models in Alzheimer's Disease, Stockholm, Sweden. The Swedish Innovation Agency (Vinnova), grant number 2021-02680.	0	2.992	N/A
28	Cubi-Molla, P., Mott, D., Henderson, Nadine., Zamora, Bernarda & Grobler, Mendel & Garau, Martina. (2023). Resource allocation in public sector programmes: does the value of a life differ between governmental departments?. Cost Effectiveness and Resource Allocation. 21. 10.1186/s12962-023-00500-5.		4	0.530	N/A

1. Google Scholar. The number of citations for each article as of October 2023

2. SCImago Journal Rank (SJR) indicator (PDF), developed by SCImago from the widely known algorithm Google PageRank™. This indicator shows the visibility of the journals contained in the Scopus® database from 1996. SJR takes into account both the number of citations received by a journal and the prestige of the journal based on where those citations come from. The latest available year of indicators is 2022.

3. Chartered Association of Business Schools ('ABS'), UK: journal rankings go from 4\* (highest) to 1 (lowest). The latest available year of rankings is 2021.

## Summary of Citations over time

Number of citations	Publication Year						Total
	2018	2019	2020	2021	2022	2023	
10+	31	14	11	11	6	N/A	73
20+	23	11	5	1	-	N/A	40
50+	12	3	3	-	-	N/A	18
100+	5	-	1	-	2	N/A	8

(See appendix for a list of all OHE publications and citations, 2018-2022).

## Top 10 Most Cited Publications since 2018

- 1,178 Citations

**Devlin, N., Shah, K., Feng, Y.,** Mulhern, B. and van Hout, B., 2018. Valuing Health-related Quality of Life: An EQ-5D-5L Value Set for England. *Health Economics*, 27(1), pp.7-22. <https://doi.org/10.1002/hec.3564>

- 893 Citations

Mulhern, B., **Feng, Y., Shah, K.,** Janssen, M.F., Herdman, M., van Hout, B. and **Devlin, N.**, 2018. Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets. *Pharmacoeconomics*, DOI: <https://doi.org/10.1007/s40273-018-0628-3>

- 221 Citations

Husereau, D., Drummond, M., Augustovski, F., de Bekker-Grob, E., Briggs, A. H., Carswell, C., et al as part of the CHEERS 2022 ISPOR Good Research Practices Task Force 2022., Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. *European Journal of Health Economics*. (Epub ahead of print). DOI: [10.1007/s10198-021-01426-6](https://doi.org/10.1007/s10198-021-01426-6).

- 146 Citations

Garrison, L.P., Neumann, P.J., Wilkie, R.J., Basu, A., Danzon, P.M., Doshi, J.A., Drummond, M.F., Lakdawalla, D.N., Pauly, M.V., Phelps, C.E., **Towse, A.** and Weinstein, M.C., 2018. A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report [7]. *Value in Health*, 21(2), pp.161-165. DOI: <https://doi.org/10.1016/j.jval.2017.12.009>

5. 119 Citations

**Hampson, G., Towse, A.,** Pearson, S., Dreitlein, W., Henshall, C., 2018. Gene Therapy: Evidence, Value and Affordability in the US Health Care System. *Journal of Comparative Effectiveness Research*, 7(1), pp.15-28. DOI: <https://doi.org/10.2217/cer-2017-0068>

6. 114 Citations

Fenwick E, **Steuten L**, Knies S, Ghabri S, Basu A, Murray JF, Koffijberg HE, Strong M, Sanders Schmidler GD, Rothery C. (2020) Value of Information Analysis for Research Decisions-An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. *Value in Health*, Feb;23(2):139-150. doi: [10.1016/j.jval.2020.01.001](https://doi.org/10.1016/j.jval.2020.01.001). PubMed PMID: [32113617](https://pubmed.ncbi.nlm.nih.gov/32113617/).

7. 106 Citations

Jonsson, B., **Hampson, G.**, Michaels, J., **Towse, A.**, Graf von der Schulenburg, J.M. and Wong, O. 2018. Advanced Therapy Medicinal Products and Health Technology Assessment Principles and Practices for Value-based and Sustainable Healthcare, *The European Journal of Health Economics*, DOI: <https://doi.org/10.1007/s10198-018-1007-x>

8. 103 Citations

Mateo, J., **Steuten, L.**, Aftimos, P., André, F., Davies, M., Garralda, E., Geissler, J., Husereau, D., Martinez-Lopez, I., Normanno, N., Reis-Filho, J., Stefani, S., Thomas, D., Westphalen, B., & Voest, E. 2022. Delivering Precision Oncology to Patients with Cancer. *Nature Medicine*. DOI: [10.1038/s41591-022-01717-2](https://doi.org/10.1038/s41591-022-01717-2)

9. 80 Citations

**Feng, Y., Devlin, N., Shah, K.**, Mulhern, B. and van Hout, B., 2018. New Methods for Modelling EQ-5D-5L Value Sets: An Application to English Data. *Health Economics*, 27(1), pp.7-22. DOI: <http://dx.doi.org/10.1002/hec.3560>

10. 76 Citations

Rothery C, Strong M, Koffijberg HE, Basu A, Ghabri S, Knies S, Murray JF, Sanders Schmidler GD, **Steuten L**, Fenwick E. (2020) Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. *Value in Health*. Mar;23(3):277-286. doi:[10.1016/j.jval.2020.01.004](https://doi.org/10.1016/j.jval.2020.01.004). PubMed PMID: [32197720](https://pubmed.ncbi.nlm.nih.gov/32197720/).

11. 76 Citations

Hobbins, A., Barry, L., Kelleher, D., **Shah, K., Devlin, N.**, Ramos Goñi, J.M. and O'Neill, C., 2018. Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L. *Pharmacoeconomics*. DOI: <https://doi.org/10.1007/s40273-018-0690-x>

12. 76 Citations

Kreimeier, S., Oppe, M., Ramos-Goñi, J.M., **Cole, A., Devlin, N.J.**, Herdman, M., Mulhern, B., **Shah, K.K.**, Stolk, E., Rivero-Arias, O. and Greiner, W., 2015. Valuation of EuroQol Five-dimensional Questionnaire, Youth Version (EQ5D-Y) and EuroQol Five-dimensional Questionnaire, Three-level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective. *Value in Health*. DOI: <https://doi.org/10.1016/j.jval.2018.05.002>



## OHE Publications (Peer-Reviewed)

No.	Publication	Sources of financial support	Number of downloads
1.	Brassel S., Firth I., Oliver E., Hampson, G., Towse A. & Steuten L. (2023) Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechanism. OHE Contract Research. Available from <a href="https://www.ohe.org/publications/incentivising-new-antibiotics-designing-value-based-delinked-pull-incentive-antibiotics/">https://www.ohe.org/publications/incentivising-new-antibiotics-designing-value-based-delinked-pull-incentive-antibiotics/</a>	Contract funded (ABPI)	115
2.	Bell E., Berdud M., Cookson G., Besley S. (2023) Delivering the Triple Win: A Value-Based Approach to Pricing. OHE Contract Research. Available from <a href="https://www.ohe.org/publications/delivering-triple-win-value-based-approach-pricing/">https://www.ohe.org/publications/delivering-triple-win-value-based-approach-pricing/</a>	Contract funded (European Federation of Pharmaceutical Industries and Associations)	125
3.	Besley, S., Cole, A., Pwu, R., Hsieh, C. (2023) Real-World Evidence: Current Best Practice for Reimbursement Decision-Making. OHE Contract Research. Available from <a href="https://www.ohe.org/publications/real-world-evidence-current-best-practice">https://www.ohe.org/publications/real-world-evidence-current-best-practice</a>	Contract funded (MSD)	150
4.	Firth, I., Pan, J., Towse, A., Steuten, L. (2023) A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance. OHE Contract Research. Available from <a href="https://www.ohe.org/publications/novel-incentive-model-uptake-diagnostics-combat-amr">https://www.ohe.org/publications/novel-incentive-model-uptake-diagnostics-combat-amr</a>	Contract funded (Roche Diagnostics)	57
5.	Sampson C., Oliver E., Radu P., Podkonjak T., Steuten L. (2023) The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe. OHE Contract Research. Available from <a href="https://www.ohe.org/publications/case-expanding-uptake-ngs-lung-cancer-eu/">https://www.ohe.org/publications/case-expanding-uptake-ngs-lung-cancer-eu/</a>	Contract funded (Takeda Pharmaceuticals America, Inc)	166
6.	Besley S., Kourouklis D., O'Neill P., Garau M. (2023) Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment. OHE Contract Research. Available from <a href="https://www.ohe.org/publications/dementia-uk-estimating-impact-research-investment">https://www.ohe.org/publications/dementia-uk-estimating-impact-research-investment</a>	Contract funded (Alzheimer's Research UK)	49
7.	Theakston C., Henderson N., Skedgel C. (2023) The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society. OHE Contract Research. Available from <a href="https://www.ohe.org/publications/burden-hidradenitis-suppurativa-recommendations/">https://www.ohe.org/publications/burden-hidradenitis-suppurativa-recommendations/</a>	Contract funded (M&F Health on behalf of Novartis)	94
8.	Besley S., Henderson N., Napier, M., Cole, A., Hampson G. (2023) Are Recommendations for HTA of Gene Therapies Being Achieved?. OHE Contract Research. Available from <a href="https://www.ohe.org/publications/recommendations-for-hta-of-gene-therapies-being-achieved/">https://www.ohe.org/publications/recommendations-for-hta-of-gene-therapies-being-achieved/</a>	Contract funded (Pfizer)	135
9.	Henderson N., Brassel S., O'Neill P., Allen R., LARGERON N., Garau M. (2023) NICE enough? Do NICE's Decision Outcomes Impact International HTA Decision-making?. OHE Contract Research. Available from <a href="https://www.ohe.org/publications/nice-enough-do-nices-decision-outcomes-impact-international-hta-decision-making/">https://www.ohe.org/publications/nice-enough-do-nices-decision-outcomes-impact-international-hta-decision-making/</a>	Contract funded (Sanofi UK)	229



## Core-funded projects

### Economics of innovation

Project	Summary	Investigators	Update on progress
Option Pricing	The use of real options in relation to pharmaceutical pricing has been promoted by the ISPOR Special Task Force on US Value Assessment Frameworks. How it can be calculated and used by payers in a way that avoids double-counting and rewards/targets investment appropriately is still being thought about. This core research project aims to move that thinking forwards via two invited editorials. The first is for <i>Value in Health</i> and will review a paper to be published. It will focus on whether payers should pay for option value. The second is for <i>Vaccine</i> . It will argue for payers being willing to add an option value to vaccine prices if this enables manufacturing capacity to be switched for use in a pandemic to be maintained.	Adrian Towse	This is now closed . There were two publications: Newall AT, Beutels P, Kis Z, Towse A, Jit M (2023). Placing a value on increased flexible vaccine manufacturing capacity for future pandemics. <i>Vaccine</i> . 2023 Mar 2:S0264-410X(23)00219-0. doi: 10.1016/j.vaccine.2023.02.065. Epub ahead of print. PMID: 36870878; PMCID: PMC9978930. Towse, A. (2022). Real Option Value: Should We Opt In or Out? Commentary. <i>Value in Health</i> Volume 25, Issue 11, 1818 – 1820 DOI: <a href="https://doi.org/10.1016/j.jval.2022.09.004">https://doi.org/10.1016/j.jval.2022.09.004</a>
The role of Product Development Partnerships (PDPs) in Pharmaceutical Innovation: are they complements or substitutes for private investment?	Product Development Partnerships (PDPs) are a rational economic response to the lack of incentives for private pharmaceutical R&D in areas of low expected returns but high unmet need (e.g., neglected tropical and infectious diseases, rare diseases). In this research, we examine: i) how different types of PDPs are associated with the likelihood of product approval, i.e., successful pharmaceutical innovation, ii) whether some types of PDPs stimulate drug development effectively in the early stages of innovation, iii) how do public and private pharmaceutical R&D investments relate to each other? Are they complements (i.e., public/donor investment incentivises private R&D in crucial areas?) or are they substitutes (i.e., public funding displaces private investment, especially in areas of low economic incentives for private investment,	Dimitrios Kourouklis, Mikel Berdud, Mireia Jofre-Bonet, Adrian Towse, Margaret Kyle (MINES ParisTech)	The paper has been published in <i>Applied Economic Letters</i> . As previously reported, in 2021 it also presented as a paper at iHEA and ISPOR Europe. The project is now closed.

	<p>iv) whether the role of the PDPs in pharmaceutical innovation, as complement or substitute, varies across different therapeutic areas, phases of the drug development and/or archetypes of health technologies (i.e., vaccines, new chemical entities, biologics, diagnostics)?</p> <p>The experience of the last decades shows that PDPs positively influence pharmaceutical innovation and access to treatment around the world by bringing new products to the market where they are needed. Literature has theoretically and empirically explored whether public funding for R&amp;D is complementary or substitutive to private funding. Although findings point out that direct government funding heavily influences the development of drugs, the evidence is non-conclusive in determining its complementary or substitutive nature. Thus, a better understanding of the relationship between private and public investment in pharmaceutical R&amp;D is necessary to identify the conditions under which public and private efforts complement each other optimally for the common good. "</p>		
The impact of R&D tax credits on pharmaceutical innovation in the UK	<p>This project studies the impact of the Research and Development Expenditure Credit (RDEC) scheme, designed to increase support for private research and development through tax credits. The use of R&amp;D tax credits is a well-recognised method for providing a fiscal incentive that will reduce the cost of R&amp;D; however, the literature has struggled to properly estimate its effect on true innovation. In general, studies fail to provide estimates on meaningful innovation and focusing on R&amp;D spending means that results are highly subject to varying efficiencies between firms.</p> <p>This research considers the treatment group to be the UK and the treatment itself to be the implementation of the RDEC in 2013. However, the problem with causal inference in this kind of study is that the counterfactual is unobservable and finding another country that can act as a suitable control may not be possible. The Synthetic Control Method (SCM), developed by Abadie and Gardeazabal (2003), will allow us to estimate the treatment effect by comparing outcomes observed in the UK to a weighted convex combination of the same outcome variables measured in other similar countries. By evaluating the effectiveness of the RDEC policy in incentivising innovation, we can help countries such as the UK evaluate its importance and therefore inform essential cost-benefit analysis. Understanding the impact of the RDEC can also help countries like the UK assess its potential use in driving innovation in specific areas of health care that need it, such as genetic research, vaccinations, or other disease areas that face scarcity in therapeutic options.</p>	Edward Oliver, Dimitrios Kourouklis Mireia Jofre-Bonet	The paper is under review at <i>Research Policy</i> . It was presented at AHEA 2022. The project is now closed.
R&D competition & diffusion of innovation in the EU: the case of Hepatitis C	<p>"The project seeks publication in a peer-reviewed journal of previous OHE Research work. We assessed the impact of (i) intellectual property protection incentives for R&amp;D, (ii) market competition, and (iii) other factors, including healthcare policies, on access to Direct Acting Antivirals (DAAs) in Europe.</p> <p>The study combined an economic framework with analyses of market shares and uptake of DAAs and interviews with relevant stakeholders of six European Countries (France, Germany, Italy, Portugal, Spain and the UK) to assess the degree and nature of market competition for DAAs between 2014Q1 and 2017Q2. The theoretical models show that current R&amp;D incentives based on IP protection in the EU can encourage in-patent competition. The uptake analyses showed that competition within the DAA class was</p>	Mikel Berdud, Martina Garau, Margherita Neri, Phill O'Neill, Chris Sampson, Adrian Towse	<u><a href="#">Published as an OHE Research Paper</a></u> . Journal write-up has been completed and the article was rejected from <i>Applied Health Economics and Health Research</i> . A resubmission is planned.

	intense in European markets soon after the launch of the first-in-class treatment. Evidence from our interviews suggested that in-class competition improved access and uptake and provided bargaining power to country payers. IP incentives for R&D may have encouraged a high degree of in-class competition among DAAs. The in-class competition positively impacted the uptake and adoption of DAAs in the top 5 European countries.		
Value of Innovative Medicines: The Case of Risperidone and Second-generation Antipsychotics?	<p>The project seeks publication in a peer-review journal of previous OHE Research work. The present work aims to assess the life-cycle value of innovative medicines based on the example of Second-Generation Antipsychotics (SGA). Using risperidone as representative of the SGA class and comparing it to haloperidol – its counterpart from the First-Generation Antipsychotics (FGA) – this research estimates a proxy of the life-cycle cost-effectiveness of the SGA class against FGA class in incremental terms. It also estimates the absolute social value-added, measured by the sum of the consumer and producer surpluses.</p> <p>This project provides evidence of the long-run cost-effectiveness of innovative medicines in Sweden and the UK. This research informs policy decision-makers, payers, and HTA bodies about the importance of balancing the view that cost per QALY estimates at launch alone are enough to guide access decisions with long-run estimates of the value added by drugs throughout their entire life cycle.</p>	Mikel Berdud, Adrian Towse, Niklas Wallin-Bernhardsson (IHE), Bernarda Zamora (independent), Peter Lindgren (IHE)	Completed. Peer review publication: Berdud, M., Wallin-Bernhardsson, N., Zamora, B., Lindgren, P., & Towse, A. (2023). The Allocation of the Economic Value of Second-Generation Antipsychotics Over the Product Life Cycle: The Case of Risperidone in Sweden and the United Kingdom. <i>Value in Health</i> , 26(3), 328-335.
Setting out the conditions in which risk-sharing schemes improve value for money	Regulators have increasingly emphasised approving potentially important treatments rapidly, notably through accelerated access schemes. As a consequence, there is a challenge for payers. Products are launched with less evidence, creating greater uncertainty about their relative effectiveness and value for money. Previous research focusing on the use of Vol approaches to conditional approval has looked only at the case for only in-research (OIR) or only with research (OWR) and not considered risk sharing as an additional option. The research question is, "when does risk-sharing improve outcomes for patients and the health system – in terms of making cost-effective treatments available when they otherwise would be delayed or not made available at all? Specifically, the results should be robust to situations in which there are differences of opinion between manufacturers and payers around the value of new technology to the health system, which are unbiased (i.e., not negotiation posturing).	Adrian Towse, Liz Fenwick (Open Health)	We have a paper under review at <i>Value in Health</i> Towse A and Fenwick E. It takes two to tango. Setting out the conditions in which performance-based risk sharing arrangements work for both parties. Under review at <i>Value in Health</i> . This is a journal article version of a 2021 OHE research paper Towse, A. and Fenwick, E., 2021. It takes two to tango: when do conditional reimbursement risk-sharing schemes work for both parties? Setting out the conditions in which risk sharing schemes improve value for money.

<p>The value of flexible vaccine manufacturing capacity: value drivers, estimation methods, and approaches to value recognition in health technology assessment</p>	<p>Expanding flexible vaccine manufacturing capacity (FVMC) for routine vaccines could facilitate more timely access to novel vaccines during future pandemics. Vaccine manufacturing capacity is 'flexible' if it is built on a technology platform that allows rapid adaption to new infectious agents. The added value of routine vaccines produced using a flexible platform for pandemic preparedness is not currently recognised in conventional health technology assessment (HTA) methods.</p> <p>We start by examining the current state of play of incentives for FVMC and exploring the relation between flexible and spare capacity. We then establish the key factors for estimating FVMC and draw from established frameworks to identify relevant value drivers including insurance value, real option value, and spillovers effects. The role of FVMC as a countermeasure against pandemic risks is deemed an additional value attribute that should be recognised.</p> <p>Next, we address the gap in the vaccine-valuation literature between the conceptual understanding of the value of FVMC and the availability of accurate and reliable tools for its estimation to facilitate integration. into HTA. Three practical approaches for estimating the value of FVMC are discussed: stated and revealed preference studies, macroeconomic modelling, and benefit-cost analysis.</p> <p>Lastly, we review how value recognition of FVMC can be realised within the HTA process for routine vaccines manufactured on flexible platforms. We argue that, while the value of FVMC is uncertain and further research is needed to help to better estimate it, the value of increased pandemic preparedness is likely to be too large to be ignored.</p>	<p>Frederick McElwee, Anthony Newall (UNSW Sydney)</p>	<p>Revise and Resubmit at <i>Pharmacoeconomics</i>.</p>
<p>Pharmaceutical policy and access to innovation in the United Kingdom after Brexit</p>	<p>Brexit was presented as an opportunity to promote innovation by breaking free from the European Union regulatory framework. Since the beginning of 2021 the Medicines and Healthcare products Regulatory Agency (MHRA) has operated as the independent regulatory agency for the United Kingdom.</p> <p>This project aims to update the first published analysis into the regulatory activity of the MHRA post Brexit. The analysis of regulatory activity of the year 2021 found that the MHRA remained reliant on EU regulatory decision-making for novel medicines and there were significant regulatory delays for a small number of novel medicines in the UK, the reasons being so far unclear. The updated analysis should cover a longer time frame and also look at access to medicines after MHRA approval.</p>	<p>Matthias Hofer</p>	<p>Project started in October 2023. We are currently exploring the option to collaborate with Imperial College London MSc program for data collection and analysis.</p>

## Value, affordability, and decision-making

Project		Investigators	Update on progress
NICE Methods Review blogs	<p>OHE responded to two NICE consultations during the review process (Dec 2020, Nov 2021), funded as core research. Following the second consultation, we prepared a series of blogs on the new NICE health technology evaluation manual. Each post provided a critical discussion on key topics, including the expected implications of the changes (or lack thereof) in the manual, what was still missing, and what further research was needed. The blogs went online between February and April (2022). The blogs are:</p> <p><a href="#">New NICE Manual for Health Technology Evaluations: A Critical Discussion on the Most Relevant Changes (or Lack Thereof)</a></p> <p><a href="#">To Hell with the 3L! NICE's Missed Opportunity to Upgrade Health Outcome Measurement Including Carer Quality of Life in Health Technology Evaluation: Are We There Yet?</a></p> <p><a href="#">The NICE Health Technology Evaluation Manual: A Fresh Perspective Needed?</a></p> <p><a href="#">NICE's severity modifier: a step in the right direction, but still a long way to go</a></p> <p><a href="#">Let's talk about (health) inequalities</a></p>	Patricia Cubi-Molla, David Mott, Eleanor Bell, Edward Oliver, Martina Garau	6 blogs were published, one of which has received over 200 views to date. The project has been closed.
Landscape analysis of country processes and stakeholder mapping for digital health technologies in England (new 2022)	<p>HITAP sought OHE to conduct a landscape analysis consisting of a review of the legal frameworks and processes involved in conducting an HTA of digital health technologies in England, and relevant stakeholders involved in the process, highlighting key issues and lessons learned in the U.K.</p> <p>OHE focussed on the regulatory framework for digital health, the process for assessing or improving digital literacy in the population, the HTA process and methods for digital health technologies. OHE further provided a mapping of relevant stakeholders, examples of a digital health technology that the national healthcare provider has reimbursed and provided lessons learned.</p>	Simon Brassel, Priscila Radu, Martina Garau, Eleanor Bell	<p>OHE provided HITAP with the report in June 2022.</p> <p>Eleanor Bell will present a related poster at the European Digital Medicine Conference in Luxembourg.</p> <p>Simon Brassel will contribute to a related panel session at HTAsiaLink 2022 in Thailand.</p> <p>HITAP's plan is to publish a report drawing from the landscape analyses of five countries to inform the future Digital Health landscape in Thailand. OHE will be co-authors of said report. The project is now closed.</p>

<p>ViH re-submission of Health System Capacity Value Publication (new 2022)</p>	<p>In December 2021, OHE completed a project funded by the ABPI vaccines group, submitting a paper to conceptualise the health system pressure of vaccines to the journal Value in Health.</p> <p>In February 2022, OHE was invited to revise and resubmit the paper following the feedback from two peer reviewers.</p> <p>The paper made policymakers aware that, in addition to preventing the outcome of interest, vaccines and other preventative health technologies deliver value in maintaining regular healthcare services and clearing the pent-up demand from the pandemic. Therefore, health system capacity value should be a key-value element in health technology assessment. Existing and potential future vaccination programs deliver more value than hitherto quantified.</p>	<p>Simon Brassel,</p>	<p>The paper was accepted by <i>Value in Health</i> and is currently in press. The project has been closed.</p>
<p>ICER pricing, bargaining, and Cost-Effectiveness Thresholds (CETs)</p>	<p>The project seeks publication in a peer-review journal of previous OHE consulting work for Roche. A novel supply and demand model of pharmaceutical markets is presented to analyse the relationship between the value of the CET and the distribution of new medicines' health and economic value between consumers (payers) and developers (life science industry). The model incorporates a bargaining process and bargaining power distributed between the payer and the developers, which impacts the distribution of the health and economic value of new medicines between the two parties.</p> <p>One of the paper's key findings is that, with a sufficiently large payer's bargaining power, an efficient CET value could be higher than the supply-side CET used for decision making. This result has important policy implications. For example, if market access for innovative medicines is based in HTA using CETs defined by the health system opportunity costs, there would be circumstances under which some cost-effective (in the long run) medicines would not be granted. This would result in reimbursement, and incentives for investing in future innovation would be undermined. This would produce inefficient resource allocation in the present, leading to not optimal innovation production in the future.</p>	<p>Mikel Berdud, Adrian Towse</p>	<p>Completed. Peer review publication: Berdud, M., Ferraro, J., &amp; Towse, A. (2023). A theory on ICER pricing and optimal levels of cost-effectiveness thresholds: a bargaining approach. <i>Frontiers in Health Services</i>, 3.</p>
<p>Digital Health Economics</p>	<p>More and more digital health technologies are entering the market and being adopted by health systems worldwide. The application of health economics differs across the spectrum of health technologies. This is, at least in part, the result of characteristic differences between pharmaceuticals, medical devices and digital health technologies (DHTs) that affect related innovation, commercialisation, evaluation and application within health systems. At present, there is no overarching framework to conceptualise how the characteristics of DHTs may affect the way these technologies are developed, launched, assessed, priced, reimbursed, and distributed. The proposed research will fill this gap by linking the summarised technology differences to their respective implication for the health economics field. The research will take the form of a narrative literature review to be published as an OHE Briefing.</p>	<p>Simon Brassel, Eleanor Bell, Martina Garau</p>	<p>The literature review is ongoing. As previously reported, initial findings were presented at an ISPOR Europe workshop in December 2021.</p>
<p>Value of life and health</p>	<p>This paper follows up on a research project with Amgen and will be submitted for publication in 2021. Government departments regularly monetise the value of a life for the purposes of informing resource allocation. In many countries, guidance documents set out the manner in which economic evaluation should be conducted, often specifying the precise values to be used for different impacts. However, we find different values of life and health are used in analyses by departments despite commonality in</p>	<p>Patricia Cubi-Molla, Martina Garau, David Mott, Nadine Henderson</p>	<p>The paper received a reject and resubmit from Cost Effectiveness and Resource</p>

	outcomes, giving rise to potential inconsistencies in decision-making and considering trade-offs within a broader public sector spending budget. Our research intends to provide some evidence to better inform the political process and raise a number of important issues on assessing the value of public expenditure across different sectors. Our targeted literature review aimed to identify thresholds, explicitly or implicitly, as observed in government-related publications, which we understand to represent the government's willingness to pay for health gain.		Allocation. It will be resubmitted in November 2023.
Defining Affordability	The objectives of this project are to Identify how 'affordability' in healthcare has been defined, described and implemented in the theoretical and empirical literature and in the UK policy debate. Propose a unified definition of affordability across different levels of healthcare decision-making and Identify possible ways to improve efficiency and consistency in how health systems handle affordability concerns.	Gayathri Kumar, Patricia Cubi-Molla, Martina Garau, Gayathri Kumar, Matthew Napier, Phill O'Neill, Chris Sampson, George Bray	Update: we have decided to turn this project into a dissertation proposal for an MSc student.
Incorporating a severity weighting into HTA: developing a tool and publishing an editorial	This project aims to develop and submit one editorial to a journal. We will use the research already completed and create an infographic that can go alongside this.  To improve the existing QALY shortfall calculator developed by OHE with funding from the ABPI. The calculator is currently in MS Excel and we propose to host it online through a web app. The calculator can be made use of by other players in this area and can be updated by the OHE as needed.	David Mott, Martina Garau	This project can now be closed as another research group has conducted this research already.
ISPOR Task Force: Antimicrobial resistance (AMR)	The objective is to describe and further develop emerging good practices for value assessment of antimicrobials, including (but not limited to) in the context of a global pull incentive. The guide will improve estimations of the significant and multifaceted wider value offered by new antimicrobials, beyond that which has routinely been captured in value assessment to date. In doing so, the guide will also be relevant to other technologies to tackle AMR, such as diagnostics, which face several of the same challenges and offer a similar value profile to new antibiotics.1 It will provide overarching recommendations on the approach(es) that should be taken and the criteria that should be considered when designing and conducting value assessment of new antibiotics and related technologies.2 It will also explore the implications of full quantitative assessment versus more pragmatic scoring approaches, as have been proposed in some jurisdictions (NHS England, 2023). Appropriate value assessment, as supported by the proposed guide to emerging good practices, will in turn support the implementation of effective pull incentives for the development of much-needed new antibiotics.	Grace Hampson	The proposal was submitted to ISPOR and suggestions for revisions have been received

<p>Around the world in HTAs blog series</p>	<p>In this Insights series, Around the World in HTAs, we shed light on HTA around the world. A general overview of the health system in the country is given, followed by how health technologies are assessed. Then some of the main challenges of the system are introduced and next steps for the future are discussed. Each blog involves a collaboration with an external author/s</p>	<p>Gayathri Kumar, Patricia Cubi-Molla, Martina Garau, Gayathri Kumar, Matthew Napier, Phill O'Neill, Chris Sampson, George Bray</p>	<p>So far 8 blogs have been released with more planned in 2024.</p>
---	---	--	---



## Policy, organisation, and incentives in health systems

Project	Summary	Investigators	Update on progress
Primary Care Valued Output	This project aims to revise and resubmit a manuscript summarising the development of a framework to measure the valued output of primary care in England. This manuscript represents the second contribution of the Health Foundation-funded Efficiency Research Programme grant.	Margherita Neri, Patricia Cubi-Molla, Graham Cookson	We recently resubmitted the manuscript from this core research project to a peer-reviewed journal, after doing some major revisions. We are now waiting for the outcome of the submission. Depending on the journal's decision to reject/accept with revisions, we may need to make some additional changes to the manuscript
The Effect of Distance on Accident and Emergency Department Demand (new 2022)	When individuals choose to attend a hospital accident and emergency department (AED), they must incur both the time and financial costs of travel, which are both likely to increase with distance. The aim of this research is to quantify the relationship between travel distance and emergency department demand using area-level regression analysis. This research will also explore the extent to which the role distance travelled plays in the decision to attend an AED is dependent on the severity of the individual's condition. This work builds upon research conducted by Sian Besley for her MSc Health Economics dissertation and the findings of this project will be submitted to a health economics journal.	Sian Besley	Sian is awaiting final analysis results tables from her external co-authors. Once the final tables are available these will be added to the manuscript draft which is near completion. Journal submission is planned for March 2024.
Healthcare budget design across emerging and developed countries (new 2022)	The Aspen Institute and Pfizer are holding a roundtable for former health and finance experts from Governments around the world. This project aimed to produce a background paper as a preface to the roundtable dialogue. The background paper covers how emerging and developed countries have approached health care budgets in the past, and how COVID-19 has changed this going forward. The background paper was prepared for an initial virtual roundtable in April 2022, with adjustments made for the in-person roundtable in October 2022.	Hannah Schirrmacher, Mireia Jofre-Bonet	The background paper was produced, and the research project has been closed.

<p>The impact of Egypt's health sector reform program on family planning and maternal and child health</p>	<p>This project aims to estimate the impact of Egypt's health sector reform program (HSRP) on family planning and maternal and child health in Egypt during the years 2000-2008. The paper highlights the impact of the HSRP on antenatal care, delivery care, women's access to health care and child morbidity prevalence. The primary data source used to assess the impact of the HSRP in Egypt on maternal and child health was a cross-sectional demographic and health survey, conducted in 2000, 2005 and 2008, the Egypt Demographic and Health Survey (EDHS).</p>	<p>Mireia Jofre-Bonet, Patricia Cubi-Molla, (Amira El-Shal)</p>	<p>3 publications; , 'Are user fees in health care always evil? Evidence from family planning, maternal, and child health services' (<i>Econ Analysis and Policy</i>), 'Accreditation as a quality-improving policy tool: family planning, maternal health, and child health in Egypt' (<i>EJHE</i>) , 'Discontinuation of performance-based financing in primary health care: Impact on family planning and maternal and child health' (<i>Int J Health Econ Manag</i>)</p>
<p>GP demand response to waiting times for suspected cancer patients</p>	<p>Reducing waiting times is a priority in many public health systems. Efforts of healthcare providers to shorten waiting times may be negated if they simultaneously induce increases in demand.</p> <p>The existing health economics literature on the demand response to waiting times focuses on elective or non-urgent care. This study adds to this literature by exploring this relationship for urgent diagnosis of suspected cancer. Early detection of cancer is a key policy concern in the UK.</p>	<p>Helen Hayes, (Rachel Meacock, University of Manchester Jonathan Stokes, University of Glasgow Matt Sutton, University of Manchester)</p>	<p>The paper is now published in the European Journal of Health Economics</p>
<p>The effects of payment unbundling on the utilisation of diagnostic imaging scans for suspected cancer patients</p>	<p>The overall aim of this study is to examine whether changes in the way that a hospital is reimbursed for diagnostic testing affects utilisation of tests for suspected cancer patients. This study examines a policy reform to the way that hospitals were reimbursed for diagnostic imaging scans, wherein a fee-for-service element was separated from the DRG-based system for hospital reimbursement for outpatient scans, also known as payment unbundling. This paper examines whether payment unbundling affected provider utilisation of scans, and conducts further analysis to ascertain whether the recorded effects represent a real change in the delivery of scans or a change in recording of scans.</p>	<p>Helen Hayes, (Rachel Meacock, University of Manchester Jonathan Stokes, University of Glasgow Matt Sutton, University of Manchester)</p>	<p>Published in Health Economics</p>

<p>The effect of local hospital waiting times on GP referrals for suspected cancer</p>	<p>Reducing waiting times is a major policy objective in publicly-funded healthcare systems. However, reductions in waiting times can produce a demand response, which may offset increases in capacity.</p> <p>We used annual counts of referrals from all 6,667 general practices to all 185 hospital Trusts in England between April 2012 and March 2018. Using a practice-level measure of local hospital waiting times based on breaches of the two-week maximum waiting time target, we examined the relationship between waiting times and urgent GP referrals for suspected cancer. To identify the sources of variation (between practices or over time) that may drive this relationship, we estimated this using three regression models: pooled linear regression, a between-practice estimator, and a within-practice estimator.</p>	<p>Helen Hayes, (Rachel Meacock, University of Manchester Jonathan Stokes, University of Glasgow Matt Sutton, University of Manchester)</p>	<p>Accepted for publication with PLOS ONE (awaiting proofs)</p>
--	---	---	---

## Measuring and valuing outcomes

Project	Summary	Investigators	Update on progress
Blocking in the design of discrete choice experiments: a review of current practice	This project relates to a collaboration with the ISPOR Health Preference Research Special Interest Group (SIG). The SIG's earlier project on preference heterogeneity (see "Accounting for preference heterogeneity in discrete-choice experiments: A survey of the state of practice") produced a literature review dataset containing hundreds of DCE studies. As an offshoot of the earlier project, a smaller project team was put together to use and build upon the existing dataset to explore blocking in experimental designs for DCEs in health. Little guidance exists relating to blocking, and the results of this subsequent review will be written up as a short manuscript reflecting on current practice.	David Mott, Nadine Henderson	The literature review has been completed and the write-up is ongoing.
Assessing the quality of life of carers of patients with cystic fibrosis manuscript	This project's aim is to (modify and) publish the WIP manuscript for the CF Carer QOL project completed in 2020, contributing to the (sparse) evidence base of carer QOL for CF carers in the UK.	David Mott, Sulayman Chowdhury	This project is ongoing.
Are QALY gains an appropriate measure of the societal value of end-of-life care?	Advocates argue that the QALY-maximisation framework systematically undervalues end-of-life care relative to curative interventions in a number of respects. First, as the primary objective of end-of-life care is not to extend survival, they suggest that it is inappropriate to consider a time element in its evaluation as in curative interventions. Second, they object to the principle that the value of a year of life is determined solely by the health-related quality of that year. This objection is based on the notion that some periods of time may be more valuable than others, including milestone moments such as weddings or birthdays or in this context, the time before death. Third, they argue that the currently constructed QALY neglects important health-related quality-of-life dimensions. These objections are collectively referred to as the 'QALY problem'.  To test these objections, we conducted a stated preference elicitation to understand public preferences for different end-of-life care scenarios, focusing on the relative importance of survival, conventional health dimensions	Chris Skedgel	The findings have been written up as a manuscript, to be submitted for consideration to a peer-reviewed journal. A "revise and resubmit" from Medical Decision Making: Policy & Practice was received in September 2023 and we are preparing the

	<p>(especially physical symptoms and anxiety), and less-conventional dimensions such as family relations, dignity, and sense of control.</p> <p>We found that although a minority of respondents strongly prioritised survival gains, most gave substantially more weight to non-health aspects. We suggest that these results argue for a broader conception of value in the context of end-of-life care.</p>		resubmission for February 2024
--	--	--	--------------------------------

## OHE events

The OHE run an array of educational virtual and face to face events with the new addition of hybrid events this year. These events include specialised webinars, roundtables, workshops, and an annual lecture as well as more informal brown-bag lunch seminars. This section provides an update on all of the OHE events held over 2023:

### Roundtables

On the 13<sup>th</sup> February, Lotte Steuten and Adrian Towse held a roundtable in Brussels, Belgium titled “AMR Pull Incentives Expert Roundtable”. 8 people were present to discuss the criteria for effective AMR pull incentives.

On the 24<sup>th</sup> April, OHE ran an expert roundtable to articulate the problem of prevention and develop recommendations moving forwards. The title of the roundtable was ‘Reimagining prevention in the UK for a prosperous health system’ and featured 10 experts across the NHS, Government, Industry and Charity sectors.

On the 19<sup>th</sup> June, Eleanor Bell, Lotte Steuten and Matthias Hofer held a roundtable discussion, sponsored by GSK entitled: ‘The Value of Vaccines to the NHS and British Economy’. There was a total of 26 people in attendance, including representatives from the NHS, Government, Industry and Charity sectors.

### OHE lunchtime and brown-bag seminars

1. On the 8th August, Gayathri Kumar, Jake Hitch and David Mott presented the preliminary findings from a EuroQol-funded project on comparing use of the OPUF tool and DCE to value EQ-5DY. This presentation was delivered as a brown-bag seminar to an audience of 13 internal staff members.
2. On the 12th of August, Priscila Radu presented the preliminary findings from her MSc dissertation in a brown bag seminar. The title of the seminar was ‘An Economic Evaluation of Next-Generation Sequencing Testing for Non-Small Cell Lung Cancer in England’. There were 12 internal staff attendees.
3. On the 31<sup>st</sup> of October, Laure de Preux (Imperial College Business School) presented Identification of the health benefits associated with the Emission Trading Scheme in Europe. There were 14 internal staff attendees.

## Webinars

1. On the 7<sup>th</sup> of February, Eleanor Bell, Sir Jonathan Van Tam, Stuart Carroll, and Ruth Dodd contributed to the webinar: *'The Value of Vaccines and Taskforces'*. The webinar, moderated by Lotte Steuten, centred on the broader value of vaccines and the role of taskforces in tackling major public health problems. This event received 158 registrants.
2. *'Considering Carer Burden in HTA'* was a 3 part webinar series taking place on the 22<sup>nd</sup> and 27<sup>th</sup> February and 2<sup>nd</sup> March. In this webinar, speakers discussed the issues in HTA measures in their capacity to adequately assess carer burden in HTA. The speakers were Portia Thorman, Chris Skedgel, Becky Pennington, David Mott, Hareth Al-Janabi, Simone Sutherland and Neil Hawkins. There were over 500 registrants per event.
3. The EVIA programme launched on the 26<sup>th</sup> April in a webinar titled, *'Valuing Vaccines: The Economics of Vaccines and Immunisation'*. The EVIA programme is an online, educational course which builds the capacity and confidence of sub-Saharan African policymakers and immunisation managers to assess costs, consequences, and value for money of vaccines. This webinar brought together global experts, Joseph Babigumira, JP Sevilla, Lotte Steuten and Eleanor Bell to discuss the value of equity in access to vaccines worldwide. There were 180 virtual attendees for this event.
4. On the 29<sup>th</sup> November, OHE presented the key findings from the Prevention report in webinar: *'Reimagining Prevention for a Healthier, More Prosperous Society'*. As well as sharing key recommendations from the report, guest speakers shared insights from their perspectives to facilitate a broad discussion of the strategies needed to increase the prioritisation of the prevention agenda.
5. In December, OHE delivered an Insights and Reflections webinar spotlighting the range of topics explored throughout the year, as well as some projections for the future.

## Sponsored Webinars

1. On the 28<sup>th</sup> February, OHE delivered a webinar that was funded by Pfizer as part of the HTA of multiple myeloma therapies project. The webinar was titled *'Evaluating Multiple Myeloma therapies: Challenges to Value Demonstration and Value Recognition'*. It included an overview of the state of play of HTA of multiple myeloma, including evidence generation challenges. The speakers included Nadine Henderson, Carole Longson, Martin Kaiser, Farzad Ali, Kate Morgan and Lotte Steuten (moderator). Having a range of industry, clinician, patient and HTA perspectives on the challenges contributed to an in-depth discussion about current practice and what needs to be done moving forwards. The event had 318 virtual attendees.
2. On the 7<sup>th</sup> June, OHE shared the key findings of the OHE Sustainability Report in a webinar, *'Supporting sustainability in the Era of Green Pharmaceuticals'*. In this ABPI funded webinar, Graham Cookson moderated a session featuring Alifia Chakera (Scottish Government), Matt Shaughnessy (AZ) and Koonal Shah (NICE). The webinar started with a short presentation on the key findings of the report and the high priority activities that could solve the challenges

presented by the climate crisis. The speakers then shared their different perspectives to capture the breadth of the challenges and solutions associated with enhancing sustainability in the UK and globally. There were 192 sign-ups for this event.

3. On the 12<sup>th</sup> August, OHE ran a Gilead funded and commissioned webinar: *'Partnerships for Health System Innovation and Improvement'*. The speakers included and there were 83 attendees. The webinar included an overview of the role of innovation in health system efficiency and the barriers that impede the adoption of innovation. It also provided the audience with real-world examples of multi-stakeholder partnerships that address the barriers to innovation adoption. The panel included Dr Jaqueline Barry (Chief Clinical Officer, Cell and Gene Therapy Catapult), Margherita Neri (Principal Economist, OHE) and Maria Vidal-Read (Head of Programme, Fast-Track Cities).
4. On the 7<sup>th</sup> December, OHE ran a Takeda sponsored webinar about NGS testing and its ability to shape the future of lung- cancer care in Europe.

### Workshops

1. On the 20<sup>th</sup> of June, OHE ran a prioritisation workshop for an ongoing project with Alzheimer's Society. In this hybrid workshop, 16 experts in the field discussed the current stage of the research and identified issues and gaps to guide the next steps. The session ended with a prioritisation activity, in which the biggest health inequalities were ranked in order of priority.
2. On the 6<sup>th</sup> July, Lotte Steuten, Amanda Cole, Mark Cabling and Sonja Marjanovik held a workshop to obtain insights from payers, policy makers and health economists. The session focussed on the topic of development in cancer diagnostic therapeutic product profiles (TPPs). Participants included experts across NICE, MHRA, DHSC, NHS England and academics. There was a total of 15 external guests attending virtually on teams.

### OHE external events

1. Innovation Policy Prize: On the 24<sup>th</sup> of January, OHE ran the Innovation Policy Prize Award Ceremony at the Royal Society of Chemistry. There was a combination of 160 virtual and in person attendees, with the event running hybrid for the first time. Graham Cookson, Adrian Towse, Anita Charlesworth took the stage. The winner of the 2022 prize was Aidan Hollis, answering the question: *'How can policymakers design a system to generate fair prices that balance access and innovation throughout the lifecycle of medicines?'*
2. Change Initiative Private Boston Launch: On the 9<sup>th</sup> of May, Charlotte Ashton and Tim Watson launched the Change Initiative at a private launch in Boston. There were 30 attendees.
3. Mass Bio Boston: Cell and Gene Therapies: On the 10<sup>th</sup> of May, Amanda Cole, Graham Cookson and Grace Hampson presented to 20 in person attendees in Boston. The title of the event was 'Cell and Gene Therapies: Can We Find Innovative Ways to Pay?' and it provided an opportunity to share insights about innovative approaches to reimbursement. The speakers also highlighted some of OHE's key research



into tackling the unique challenges that cell and gene therapies create for industry, regulators, and payers. Finally, the uncertainty surrounding patient access was addressed and discussed.

4. 2023 Annual Lecture: On the 13<sup>th</sup> of September, OHE brought Climate- Change Economist, Prof. Elizabeth Robinson to the stage to present her knowledge of the interplay between health and the environment. This lecture outlined importance of a one-health perspective when exploring the integral steps needed to transition to a climate-resilient future. The title of the lecture was *'The Economics of Health: Fostering Well-being, Sustainable Livelihoods and a Greener Future'*. There were 202 registrants, and the event was delivered in a hybrid format, livestreamed from the Royal Society of Medicine. The event was followed by a drinks and networking reception.

## External impact (beyond scientific citations)

In this section we aim to provide an idea of the impact of OHE research that goes beyond the number of publications and/or scientific citations. We first present a selection of impactful outputs by other metrics, and, we illustrate some of this impact with some summary statistics of the downloads and visits to our website, as well as a list of our advisory roles and external presentations.

- Selection of Impactful Research Outputs

In 2023, OHE's research has had impact across an impressive range and depth of topics. The following is a selection of the most notable, based on level of activity, digital channel metrics and broader coverage.

### Inflation Reduction Act

- OHE kicked off a busy year of providing insight and analysis on the impact of the Inflation Reduction act on drug development with an [ISPOR 2023 panel](#). At the conference, a [free IRA educational program](#) was also launched.
- OHE continued speaking to key audiences with a [pre-congress session](#) at IHEA 2023 and a [Panel at DIA conference \(at pharmaceutical commerce\)](#)
- As a result of the above activities, OHE was invited to comment in an [Evidence base interview](#) with Amanda Cole (OHE)
- OHE also used its own channels - publishing an Insight piece and leading with an editorial on the topic for the May 2023 issue of the OHE Bulletin.

### HTA bodies

- OHE continues to be viewed as a leading voice on HTA bodies, both in the UK and internationally as evidenced most recently with the publication of the 'NICE Enough?' report which is already the most-downloaded of the reports published in 2023 and received a lot of attention on LinkedIn
- OHE also started an Insight series 'Around the World in HTAs' which has enjoyed a strong profile on our social channels and, through joint authorship, helped build our broader network.
- OHE inputted into specific HTA questions in a number of key areas, including
  - Estimating the most appropriate discount rate for the Slovak Republic - an Insight was published and the analysis has been shared with government officials for consideration
  - OHE's previous work on HTA of gene therapies was followed up with the publication of a country scorecard assessment which [led to coverage in industry title the Pink Sheet](#)

### Sustainability

- OHE's Supporting the Era of Green Pharmaceuticals in the UK report, published in November 2022 was the most downloaded report of 2023 and provided a springboard to a range of activities in 2023.
- OHE held a webinar on the findings of the report, which attracted more than 200 registrants, it was involved in establishing the ISPOR SIG, published journal articles and presented a panel at ISPOR 2023.
- OHE also chose sustainability as the topic for the 2023 Annual Lecture which attracted more than 200 registrants.
- Sustainability is also one of the two broad themes that the Change Initiative will be focused on when it launches.

## AMR

- Published an [OHE report](#) on incentivising new antibiotics ([cited at Pharmavoice](#))
- OHE published the first blog on AMR "[Breaking the European Deadlock](#)" of a series of four planned
- There was a citation of [OHE TEE work](#) for EFPIA [at Lancet](#)
- OHE will also publish a series of three reports in November related to the NICE/NHS England AMR Pilot. The substance of which also informed an OHE submission to the public consultation which ran July-October 2023. An Insight exploring some of the recommendations submitted will also be published in November.

## Other notable mentions:

**Dementia** - OHE worked with Alzheimer's Research UK to estimate the likelihood of developing dementia, being a carer, or both. The associated campaign achieved coverage which included the [Daily Express](#) and [The Sun](#).

**Digital health** - OHE's report, Navigating the Landscape of Digital Health - UK, published in December 2022, was picked up by some influential voices on LinkedIn. As a result of them sharing it with their extensive networks, and driving significant traffic to the OHE website, it is the second most downloaded report in 2023.

**NGS** - The second most downloaded report that was published in 2023, The Case for Expanding Updated of NGS for Lung Cancer, also secured a range of coverage, including key industry title [GenomeWeb](#) and for a much broader audience, the [Mail on Sunday](#).

## Website, Insights & Social Media


We have continued to have substantial activity on our website, which was relaunched in January, and our social media channels are growing. We have achieved the following reach as in 2023:

- Number of research insights (previously termed blogs) published on website: 20 (plus 9 bulletins and 5 news updates, compared to 27 updates in the same period of 2022)
- Number of publication downloads: 6,132 (compared to 12,535 in the same period of 2022)
- Number of website visits: 89,104 (compared to 185,702 in the same period of 2022)
- Mailing list subscribers: 9,533 (compared to 14,133 in 2022)
- LinkedIn Followers: 9,926 (compared to 7,342 in 2022)
- Twitter followers: 5843 (compared to 5,539 in 2022)

The transition to our new website involved some downtime, and also changed how our analytics are measured. Our newer analytics are more conservative, as repeat views of the same page are now measured as a single 'visit', and users are also able to opt-out of monitoring of their visits and downloads for privacy reasons. Therefore, we caution against overinterpreting the slightly decreases in our website activity compared to 2022. Our website analytics also demonstrate the geographic reach of our website. We have over 34,535 users in 165 countries.

This year we also carried out an exercise to refine our mailing list, by removing duplicates, addresses sending bounce backs, and individuals who had not interacted with our last 15 emails. Our total mailing list has therefore reduced from 14,122 to 9,533. Our monthly newsletter operates on an 'opt in' basis and we circulate it to 5,610 people.

Figure 1: Top 10 locations for OHE website users



When looking at the top downloads in 2023, highest interest and impact is observed in OHE publications on value-based pricing and NICE decision making, green pharmaceuticals, and the health technology assessment of innovative technologies like gene-therapies, novel antimicrobials, next-generation sequencing, and digital health.

Figure 2: Top 5 downloads of 2023 OHE Reports in the year 2023.





Figure 3: Top 5 downloads of all OHE reports in the year 2023.



## Advisory roles

The number of advisory roles of OHE staff members has continued to grow. It reflects the good standing of OHE members in terms of impacting policy and our recognised contribution to the wider research and policy community. Having an impact and helping steer health policy and decision-making in health economics is an essential OHE charitable object.

## OHE staff membership of advisory panels, boards and committees

### Advisory Panels

1. NICE: Member of the Expert Advisers Panel for the Centre for Guidelines – Mireia Jofre-Bonet
2. UKRI/ESRC/MRC – Peer Review College - Mireia Jofre-Bonet
3. ISPOR: Member of the 'Value of Information' Task Force – Lotte Steuten
4. NIHR: Steering Committee Member for NIHR/HS&DR Project No. 8/17/1934 – Graham Cookson
5. NIHR – Member of a Study Steering Committee for the LOGiC – Long term Outcomes for Gender Identity in Children Study – funded by NIHR. Sites: Tavistock and Portman-NHS; UCL; U. Liverpool, U. Cambridge, UCLH - Mireia Jofre-Bonet
6. NIHR – Member of a Study Steering Committee for ADVANCE - National Addiction Centre Institute of Psychiatry, Psychology and Neuroscience - King's College London- Mireia Jofre-Bonet
7. NIHR - Member of a Study Steering Committee for the SUpporting Wellbeing Through PEer-Befriending (SUPERB) Trial – City, University of London, and UCLH, Kings College - Mireia Jofre-Bonet
8. Health Foundation – Member of the Steering Committee for NHS Workforce Retention Project – Graham Cookson
9. Scientific Experts and Methodologists Group (SEM) Delphi Panel Member of the IMPACT-HTA (WP7) project “Improved methods and actionable tools for enhancing HTA” – Martina Garau
10. Health Economics, Heads of Unit, UK : Convenor – jointly with Joanne Coast - Mireia Jofre-Bonet
11. Applied Health Economics and Health Policy Journal : Editorial Board Member – Lotte Steuten
12. PharmacoEconomics: Editorial Board Member – Chris Skedgel
13. ISPOR Member Finance Committee – Adrian Towse
14. ISPOR Chair Governance Committee – Adrian Towse
15. ISPOR Member ISPOR Health Science Policy Committee – Adrian Towse
16. ISPOR Member ISPOR Nominations Committee. – Adrian Towse

17. Participant in the Efficient and Effective Reduction of Health Inequality Workshop #2, Centre for Health Economics, University of York, which was held via Zoom on Tuesday 10th November 2020 – Mireia Jofre-Bonet
18. EuroQol: Member of EuroQol Group Association (and its Valuation Working Group) – David Mott
19. ISPOR Co-Chair ISPOR Europe 2021 – Lotte Steuten
20. ISPOR Director ISPOR Board – Lotte Steuten
21. ISPOR Steering Group Member of ISPOR Taskforce on Value-Based Healthcare – Lotte Steuten
22. Steering Committee of the project 'Antenas de innovacion y difusion en Politica Sanitaria' (Innovation and Dissemination in Health Policy Radar) led by the Centre de Recerca en Economia de la Salut (CRES) of the Universitat Pompeu Fabra (UPF), sponsored by Astra-Zeneca – Mireia Jofre-Bonet
23. EuroQoL : Member of EuroQol Group Association – Chris Sampson
24. ISPOR Member of the Health Science Policy Council (Policy Outlook Committee) – Amanda Cole
25. COMPASS Pathways Technical Advisory Board – Mireia Jofre-Bonet
26. Member of the judging panel for the research grant "Becas de investigacion en Economia de la Salud", awarded by the Spanish Health Economics Association (AES), funder: Novartis – Patricia Cubi-Molla
27. Peer Review of Grants by "la Caixa" Foundation, Spain – Mireia Jofre-Bonet
28. PLOS One: Editorial Board of peer reviewed journal– Mireia Jofre-Bonet
29. Visiting Researcher at Imperial College Business School Centre for Health Economics & Policy Innovation – Matthias Hofer
30. Non-Resident Fellow of the Center for Global Development – Adrian Towse
31. Mireia- Jofre-Bonet asked to be Member of the recruiting Panel for a Health Economist for the for the CRUK Convergence Science Centre at The Institute of Cancer Research and Imperial College.
32. NHS England Primary Care Transformation Programme: Quantitative Working Group - Graham

### Research interest groups

33. ISPOR: Statistical Methods in Health Economics and Outcomes Research Special Interest Group Member – Graham Cookson
34. ISPOR: Oncology Special Interest Group Member – Graham Cookson
35. ISPOR: Rare Disease Special Interest Group Member – Graham Cookson
36. ISPOR: Health Preference Research Group Member – David Mott
37. ISPOR: Medical Devices and Diagnostics Special Interest Group member – Amanda Cole
38. iHEA: Member of the 'health systems' efficiency' interest group – Margherita Neri
39. IHEA Mental Health Economics Special Interest Group – Chris Sampson (Lead Convenor)



40. AES: Evaluation of Health Policies and Health Care Services (EvaluAES) Member – Patricia Cubí-Mollá
41. ISPOR: Digital Health Special Interest Group member - Simon Brassel, Chris Sampson

### Visiting positions for OHE staff

42. Nuffield Department of Population Health, University of Oxford – Senior Visiting Fellow – Adrian Towse
43. Public University of Navarra – Visiting Researcher – Mikel Berdud
44. University of Surrey – Visiting Professor – Graham Cookson
45. City, University of London – Honorary Visiting Professor, Department of Economics – Lotte Steuten
46. City, University of London – Honorary Visiting Professor, Department of Economics – Graham Cookson
47. City, University of London – Honorary Visiting Professor, Department of Economics – Mireia Jofre-Bonet
48. City, University of London – Honorary Senior Research Fellow– Patricia Cubí-Mollá
49. Fred Hutch Cancer Research Center, University of Washington – Affiliate Investigator – Lotte Steuten
50. University of East Anglia – Honorary Senior Fellow – Chris Skedgel
51. Centre for Industrial Economics, MINES ParisTech – Research Associate - Dimitrios Kourouklis – renewed 2022-2025
52. Associated Visiting Researcher, Centre de Recerca en Economia de la Salut (CRES), Universitat Pompeu Fabra, Barcelona, Spain – Mireia Jofre-Bonet
53. Imperial College Business School-Centre for Health Economics & Policy and Innovation Visiting Researcher– Matthias Hofer
54. Centre de Recerca en Economia de la Salut (CRES), Universitat Pompeu Fabra, Barcelona, Spain – Senior Associate Researcher, , Mireia Jofre-Bonet
55. LSE, Visiting Professor in Practice until 5th September 2025 – Adrian Towse
56. Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford : Senior Visiting Fellow – Adrian Towse
57. Honorary Professor of Practice, University College London (UCL), Amanda Cole

## External presentations

No.	Presentation Details
1	<p>Date: 11th January 2023            Presenter: Mireia Jofre-Bonet  <b>Event: Health Economics Study Group Meeting - Winter 2023</b>            Location: Manchester            Presentation title: Discussion of the paper "A Prescription for Knowledge: Patient Information and Generic Substitution"            What was your presentation about? This paper analyses the effect of consumer information on the use of generic drugs exploiting data on claims after a large Swiss health insurer sent letters to inform patients about the possibility of generic substitution. The authors use an event study design to estimate the causal effect of the informative letter on the probability of using a generic alternative and causal forests to examine treatment effect heterogeneity. They find that the insurer letter increases the probability of using a generic alternative by 30 percentage points and that the effect is stronger: on patients receiving drugs directly from physicians; if they have to cost share; Swiss citizens; of older age, and the larger the relative price differences are.            Authors: Linn Hjalmarsson, Christian P.R. Schmid, Nicolas Schreiner.</p>
2	<p>Date: 13th January 2023            Presenter: Sian Besley  <b>Event: Health Economics Study Group Meeting - Winter 2023</b>            Location: Manchester            Presentation title: The Effect of Distance on Accident and Emergency Department Demand            What was your presentation about?            The presentation explored the findings of regression analysis used to determine the effect of distance on accident and emergency department demand. The analysis also explored how the urgency of patients conditions impacts the role that distance plays in the decision to access emergency healthcare.            Authors: Sian Besley, Rita Santos, Peter Sivey</p>
3	<p>Date 12th January 2023            Presenter Nadine Henderson  <b>Event Health Economics Study Group Meeting - Winter 2023</b>            Location Manchester            Discussion of "Development of an adapted EQ-5D-3L for adults who have a mild to moderate learning disability"            As per the HESG format, I summarised the above paper and discussed its strengths and limitations, making recommendations to improve the paper.            Author of the paper: John O'Dwyer (University of Leeds)</p>
4	<p>Date: 12th January 2023            Presenter: Gayathri Kumar  <b>Event: Health Economics Study Group Meeting - Winter 2023</b>            Location: Manchester            Presentation title: Discussion of "Healthcare or societal? NICE's approach to perspective in economic evaluations"            What was your presentation about? Critical appraisal of NICE's working paper outlining their choice to continue using the healthcare system perspective over the societal perspective            Authors: James Love-Koh and Koonal Shah</p>

5	<p>Date: 12th January 2023  Presenter: Chris Sampson  <b>Event: Health Economics Study Group Meeting - Winter 2023</b>  Location: Manchester  Presentation title: Do we need animal health economics?  What was your presentation about? In this narrative review and discussion paper, we explore whether there is a need for animal health economics. The study of animal health economics should involve numerous disciplines beyond veterinary science and economics, with important questions for political science, ecology, and ethics. We conclude by arguing that health economists should consider dedicating more energy to research on animal health.  Authors: Chris Sampson, Hareth Al-Janabi, Louise Proud, Stefan Lipman, Werner Brouwer</p>
6	<p>Date: 13 February 2023  Presenter: Amanda Cole  <b>Event: Guest Lecture for UCL's MBA in Health programme</b>  Location: One Canada Square, Canary Wharf, London  Presentation title: Outcome-based payment in the life sciences industry  Through this lecture, Amanda explained and discussed with the MBA students the key motivations for moving away from a "one price for one drug" model, and described the what, why and why now of outcome-based payment models, including their current and potential future role in the UK medicine landscape.</p>
7	<p>Date 6<sup>th</sup> March 2023  Presenter Graham Cookson  <b>Event Green Era of Pharmaceuticals</b>  Presentation to Scottish Government &amp; Scottish NHS  Graham Cookson, Isobel Firth, Jake Hitch, Nadine Henderson</p>
8	<p>Date 14th March 2023  Presenters Nadine Henderson &amp; Jake Hitch  <b>Event: Presentation to PMCPA,</b>  Introduction to Health Economics  To give PMCPA staff an overview of Health Economics concepts that may be relevant when assessing Code complaints and cases.  What was your presentation about? The presentation was a high-level overview of fundamental concepts in health economics including HTA, economic evaluation, QALYs, HRQoL, ICERs and sensitivity analysis  Authors: Jake Hitch, Nadine Henderson</p>
9	<p>Date: 6<sup>th</sup> and 7<sup>th</sup> March 2023  Presenter: Mireia Jofre-Bonet  <b>Event: MSc in Economics of the Economics Department of the University of Malta</b>  Location: Malta  Presentation title:  Lectures on Health Economics and Economic Evaluation</p>

	<p>What was your presentation about? Introduction to Health Economics and Economic Evaluation</p> <p>Authors: N/A</p>
10	<p>Date: 23rd March 2023</p> <p>Presenter: Mikel Berdud</p> <p><b>Event: Lecture on Health Economics to MSc program (module: Health Economics)</b></p> <p>Location: City University of London, London, UK</p> <p>Presentation title: Economics of Pharmaceutical Markets</p> <p>What was your presentation about? the presentation went through the process of pharmaceutical R&amp;D, methods for R&amp;D cost estimation of a ne medicine, market failures, IP protection, Value-based Pricing, Push and Pull incentives, AMR and Orphan Drugs.</p> <p>Authors: Mikel Berdud</p>
11	<p>Date: 13th April 2023</p> <p>Presenter: Adrian Towse</p> <p><b>Event: Global Coalition on Aging (GCOA) Virtual Workshop: The Value Of Pull Incentives In Japan To Encourage Investment In Antibiotic Innovation To Solve The AMR Crisis</b></p> <p>Location: Virtual</p> <p>Presentation title: " Pull Mechanisms for New Antibiotics: Calculating Japan's ROI from a Great Investment"</p> <p>What was your presentation about? Results for Japan of work undertaken for the Center for Global Development on the returns of investing in new drugs to tackle AMR. This was part of a Workshop which included presenters from the governments of Japan, Sweden, the US and the UK.</p> <p>Authors: Adrian Towse and Rachel Silverman Bonnifield</p>
12	<p>Date: 19 April 2023</p> <p>Presenter: Lotte Steuten and Amanda Cole</p> <p><b>Event: LSE Market Access Executive Course</b></p> <p>Location: LSE - London, UK</p> <p>Title: Making outcomes-based payment a reality in the NHS. // Summary of CRUK-funded research on feasibility and practical challenges around OBP in the NHS.</p> <p>Authors: Lotte Steuten &amp; Amanda Cole</p>
13	<p>Date: 25th April 2023</p> <p>Presenter: Adrian Towse</p> <p><b>Event: CGD virtual debate, "Do Patents Promote Health Innovation in Low- and Middle- Income Countries?"</b></p> <p>Location: Virtual</p> <p>Presentation title: " Yes, Patents Do Promote Health Innovation in Low- and Middle- Income Countries"</p> <p>What was your presentation about? It set out the case that patents were improving the health of low and middle income populations and over time, for key middle income countries, would promote health innovation (via a science base) in those countries.</p> <p>Authors: Adrian Towse. Co-proposer was Anita McGahan, University Professor and George E. Connell Chair in Organizations and Society, University of Toronto. Opposers were Carlos Correa, Executive Director, South Centre and Cassandra Sweet, Senior Consultant, United Nations.</p>
14	<p>Date 7<sup>th</sup> May 2023</p> <p>Presenter Lotte Steuten</p> <p><b>Event: ISPOR 2023,</b></p> <p>Location: Boston, USA.</p>

	<p>Core Concepts and Approaches to Early-Stage Health Technology Assessment , Short Course</p> <p>The course aimed to demystify the objectives of early-stage health technology assessment and the methods of translational health economics. Students in the course gain a thorough understanding of available methods for early-stage technology assessment, the specific challenges and solutions, and a clear sense of how to implement this in the complexity of health technology development, funding, regulation, pricing, and reimbursement. The course utilizes real-world examples and students will have the opportunity to strategize about the creation of a research plan for their purposes.</p> <p>Faculty: Lotte Steuten, PhD, Office of Health Economics, London, UK William Canestaro, PhD, MSc, Washington Research Foundation, Seattle, WA, USA; Erik Landaas, PhD, MPH, W. L. Gore &amp; Associates, Inc., Flagstaff, AZ, USA</p>
15	<p>Date: 7th May 2023 Presenter: Adrian Towse <b>Event: ISPOR Annual Meeting USA</b> Location: ISPOR 2023, Boston, USA. Presentation title: "Theory and Incentives in Risk Sharing" What was your presentation about? Part of a Short Course given with Lou Garrison and Josh Carlson of UW. My section addresses the theory and practice of risk-sharing agreements with case studies. Authors: Adrian Towse</p>
16	<p>Date: 8th May 2023 Presenter: Chris Sampson <b>Event: ISPOR Annual Meeting U.S.</b> Location: Boston, US Presentation title: Pocket-Sized Solutions: How Can We Balance Value, Evidence, and Stakeholder Needs for Digital Therapeutics? [Issue Panel] What was your presentation about? I described our research evaluating Sleepio, the first DTx recommended by NICE in the UK. I summarised NICE's evidence standards framework for digital health technologies and consumer-facing guidance in the UK, highlighting the limitations of current guidance. Authors: Chris Sampson</p>
17	<p>Date: 8th May 2023 Presenter: Amanda Cole <b>Event: ISPOR Annual Meeting 2023</b> Location: Boston, USA Presentation Title: Towards broader relevance for HEOR: an HSPC visioning project. Topic: HEOR has focused mainly on single technology assessment (STA) and has evolved excellent methods for it, with ISPOR having been a leading organization in this field. However, while use of HEOR has been strong for real world healthcare decisions for single technologies in some countries, it is weaker in others. How can we improve the useability and applicability of HEOR? Draft findings of an HSPC working group on this topic, including the observed challenges to HEOR use, further opportunities in HEOR use for STA, the role of health system organization incentives in healthcare decisions, implementation considerations, and the need to adapt methods and data collection to better inform decisions in areas such as disease management and public health. Authors: Willke R, McElwee N, Cole A, Berger M, Earnshaw S</p>
18	<p>Date: 8<sup>th</sup> May 2023: Moderator: Lotte Steuten. <b>Event: ISPOR Annual Meeting 2023</b></p>

	<p>Location: Boston, USA  Presentation Title : Issue Panel - Considering the Impact of the Inflation Reduction Act on Drug Development and Patients.  Topic: Discussion of the likely impact of US Inflation Reduction Act from the perspective of investors, policy makers and patients.  Authors: Cole A, Cookson G, Steuten L.</p>
19	<p>Date: 9th May 2023  Presenter: Amanda Cole  <b>Event: ISPOR Annual Meeting 2023</b>  Location: Boston, USA  Presentation Title: Explaining the Inflation Reduction Act  Topic: The objective of the Educational Symposium was to provide an accessible explanation of the technical detail of the IRA and a contextual overview of where it came from.  Authors: Cookson G, Axelsen K &amp; Cole A.</p>
20	<p>Date: 9<sup>th</sup> May 2023  Moderator: Lotte Steuten.  <b>Event: ISPOR Annual Meeting 2023</b>  Location: Boston, USA  Presentation Title: ISPOR Forum: Using HEOR Methods for Improving the Implementation of Value-Based Healthcare  Topic: update on the progress of ISPOR Special Taskforce on HEOR methods to improve VBHC implementation.  Authors: Steuten L &amp; Grueger J.</p>
21	<p>Date: 12th May 2023  Presenter: Mikel Berdud  <b>Event: XII TALLER EVALUAES - INVESTIGACIÓN EN EVALUACIÓN DE POLÍTICAS Y SERVICIOS DE SALUD</b>  Location: Bilbao, Spain  Presentation title: Disentangling the value equation: a step forward in value-based health care  What was your presentation about? It was a discussant presentation for a work in progress by Borja Garcia-Lorenzo and coauthors on the topic of the title of the presentation. It was a technical paper proposing a new method to aggregate components of value e.g. patient reported outcomes and clinical outcomes into the value equation for its use in decision making  Authors: Mikel Berdud</p>
22	<p>Date: 10th May 2023  Presenter: Amanda Cole, Graham Cookson and Grace Hampson  <b>Event: Cell &amp; Gene Therapies Seminar, MassBio</b>  Location: Boston, USA  Presentation Title: Reimbursement for Cell &amp; Gene Therapies: Can We Find Innovative Ways to Pay?  Topic: Tackling the unique challenges that cell and gene therapies create for industry, regulators, and payors. Could innovative payment models help deal with the challenges?  Authors: Cookson G, Cole A &amp; Hampson G.</p>
23	<p>Date: 24<sup>th</sup> May 2023  Presenter: Grace Hampson  <b>Event: LSE Market Access Executive Course</b>  Location: LSE - London, UK  Title: Reimbursement for Cell &amp; Gene Therapies: Can We Find Innovative Ways to Pay?  Authors: Grace Hampson</p>

24	<p>Date: 14th June 2023  Presenter: Eleanor Bell  <b>Event: Meeting of Turkish Association of Research-Based Pharmaceutical Countries</b>  Location: virtual  Presentation title: Value-based pricing for pharmaceuticals: lessons form Europe  What was your presentation about: learnings from implementation of value-based approaches in Europe  Authors: Eleanor Bell, Mikel Berdud, Sian Besley, Graham Cookson</p>
25	<p>Date: 14 June 2023  Chris Skedgel  <b>Pharma Client Corporate Summit</b>  Zurich, Switzerland  "Brace for Impact: anticipating the impact of the changing HTA landscape"</p>
26	<p>Date: 14 June 2023  Presenter Chris Skedgel  <b>Event Online Progress Educational Trust (PET) Webinar</b>  Location Online  Presentation title  Health economic perspective on assisted reproductive therapies</p>
27	<p>Date 16<sup>th</sup> June 2023  Presenter Graham Cookson  <b>Event Sandpit on Environmental Sustainable Healthcare</b>  Location Panmure House Edinburgh  Invitation to sandpit on the economics of environmentally sustainable healthcare  Brainstorming session with key individuals from government and Academia discussing barriers to incorporating sustainability into procurement within healthcare.</p>
28	<p>Date: 19th June 2023  Presenter: Adrian Towse  <b>Event: Australian Government HTA Review Reference Committee Meeting</b>  Location: Adelaide Australia.  Presentation title: "Experience of CED and Risk Sharing Schemes in the UK and elsewhere."  My remarks on the practical issues in CED and risk sharing – for example the UK CDF and the MS RSS - introduced a discussion with the review panel on the challenges of implementing "only with research" options within a HTA system.  Authors: Adrian Towse</p>
29	<p>Date: 20th June 2023</p>

	<p>Presenter: Adrian Towse</p> <p><b>Event: Bellberry Fourth International Scientific Congress: "Towards a Coordinated Approach for Managing Accelerated Patient Access to Potentially Beneficial Medicines".</b></p> <p>Location: Adelaide, Australia</p> <p>Presentation title: " The changing nature of drug discovery and innovation."</p> <p>This presentation was a response to a presentation by Dr Craig Tendler, Vice President and Global Head of Clinical Development, Oncology, Janssen Research &amp; Development. My presentation addressed the question "Is science driving the move into more areas where accelerated access is available, or is the availability of faster access and lower initial evidence requirements distorting R&amp;D decision making?"</p> <p>Authors: Adrian Towse</p>
30	<p>Date: 23<sup>rd</sup> June 2023</p> <p>Presenter Mireia Jofre-Bonet</p> <p><b>Event: Health Economics Study Group Meeting - Summer 2023</b></p> <p>Location: Oxford</p> <p>Presentation title: Discussant of the paper 'Childhood transitions between weight status categories incorporating complex survey design: Evidence from the Millennium Cohort Study' by Olu Onyemadu.</p>
31	<p>Date: 26th June 2023</p> <p>Presenter: Chris Sampson</p> <p><b>Event: QMUL Mental Health Economics Event Series</b></p> <p>Location: Online</p> <p>Presentation title: Economics of student mental health: crisis and cultivation</p> <p>What was your presentation about? An overview of health economics research in student mental health.</p> <p>Authors: Chris Sampson</p>
32	<p>Date: 26th June 2023</p> <p>Presenter: Martina Garau</p> <p><b>Event: HTAi 2023 annual meeting</b></p> <p>Location: Adelaide (Australia)</p> <p>Presentation title: HTA reforms: An international comparison</p> <p>What was your presentation about? HTA methods &amp; processes (M&amp;P) vary across jurisdictions and have changed over time. Our study looks at the dynamic evolution of a set of HTA systems around the world.</p> <p>Authors: Eleanor Bell; Patricia Cubi-Molla; Martina Garau; Gayathri Kumar; Jia Pan; Priscila Radu; Carl Baxter; Ramiro Gilardino; Melinda Goodall; Julie Van Bavel</p>
33	<p>Date: 27th June 2023</p> <p>Presenter: Martina Garau</p> <p><b>Event: HTAi 2023 annual meeting</b></p> <p>Location: Adelaide (Australia)</p> <p>Presentation title: A Qualitative Exploration of NICE's Impact on International Health Technology Assessment.</p> <p>What was your presentation about? The English National Institute for Health and Care Excellence (NICE) plays a prominent role. However, there is limited evidence on the extent to which this is the case and, if it is, how NICE's decision outcomes on individual interventions affect HTA in other countries. We explored the impact of NICE's decision outcomes and its potential underlying factors in countries across the world using qualitative and quantitative research methods.</p>



	Authors: Nadine Henderson, Simon Brassel, Ilana Gibbons, Rachel Allen, Nathalie Largeron, Martina Garau
34	<p>Date: 27th June 2023</p> <p>Presenter: Dr. Dimitrios Kourouklis</p> <p><b>Event: DIA Global Annual Meeting</b></p> <p>Location: Boston</p> <p>Presentation title: The Inflation Reduction Act Price Setting: What are the Impacts on Biopharmaceutical Innovation from Different Perspectives?</p> <p>What was your presentation about? Explain how pricing reforms included in the Inflation Reduction Act (IRA) will work; Identify the type of medicines and conditions that are likely to be affected; Discuss its potential consequences on the market conditions, in particular on patients and pharmaceutical developers, and relevant learnings from the US and European experience of price regulation.</p> <p>Authors: Dimitrios Kourouklis, Jake Hitch, Amanda Cole, Graham Cookson</p>
35	<p>Date: 5th July 2023</p> <p>Presenter: Patricia Cubi-Molla</p> <p><b>Event: Spanish Health Economics conference (AES XLII)</b></p> <p>Location: Girona (Spain)</p> <p>Presentation title: Does the value of a life differ between governmental departments?</p> <p>What was your presentation about? Resource allocation in public sector programmes</p> <p>Authors: Patricia Cubi-Molla, David Mott, Nadine Henderson, Bernarda Zamora, Mendel Grobler, Martina Garau</p>
36	<p>Date: 6th July 2023</p> <p>Presenter: Patricia Cubi-Molla</p> <p><b>Event: Spanish Health Economics conference (AES XLII)</b></p> <p>Location: Girona (Spain)</p> <p>Presentation title: Efficiency And Impact Of Skill-Mix (And Technology) On Productivity</p> <p>What was your presentation about? Initial results on the research project that evaluates the efficiency on primary care in England - on average, general practices in England show high technical efficiency levels</p> <p>Authors: Margherita Neri, Bruce Hollingsworth, Eugenio Zucchelli , Patricia Cubi-Molla, Graham Cookson</p>
37	<p>Date: 9th July 2023</p> <p>Presenter: Amanda Cole and Graham Cookson</p> <p><b>Event: iHEA Congress</b></p> <p>Location: Cape Town, South Africa</p> <p>Presentation: Anticipating the Potential Impacts of the Inflation Reduction Act (IRA) in the U.S.: What can be Learnt from Global Experience on the Impact of Price Regulation on Patient Access and Equity of Access?</p> <p>Topic: Understanding the innovation impact of the IRA within and outside the US.</p> <p>Authors: Cole, A. &amp; Cookson, G.</p>
38	Date: 10th July 2023

	<p>Presenter: Sian Besley</p> <p><b>Event: iHEA</b></p> <p>Location: Cape Town, South Africa</p> <p>Presentation title: Healthcare System Sustainability and Resilience: Creating an Index</p> <p>What was your presentation about? This was a poster presentation discussing the development of a country-level index that will enable countries to quantitatively assess potential areas of strength and weakness not only within their healthcare system but external factors which can impact the sustainability and resilience of the healthcare system. The final outcome is the Healthcare System Sustainability and Resilience Index (HSSRI) which we piloted using data from 5 high-income countries: France, Germany, Poland, Japan, and the United Kingdom.</p> <p>Authors: Sian Besley, Dimitrios Kourouklis, Mireia Jofre-Bonet, Alistair McGuire, George Wharton</p>
39	<p>Date: 10th July 2023</p> <p>Presenter: Margherita Neri</p> <p><b>Event: iHEA World Congress</b></p> <p>Location: Cape Town, South Africa</p> <p>Presentation title: Efficiency And Impact Of Skill-Mix And Technology On Productivity. Evidence From General Practices In England</p> <p>What was your presentation about? This presentation discussed the initial results of an empirical analysis of efficiency across general practices in England and of the determinants of productivity, including staff skill mix and technology.</p> <p>Authors: Margherita Neri, Bruce Hollingsworth, Eugenio Zucchelli, Patricia Cubi-Molla, Graham Cookson</p>
40	<p>Date: 18 September 2023</p> <p>Presenter: Mireia Jofre-Bonet</p> <p><b>Event: VIII Expert Programme in Health Policy and Pharmacoeconomics</b></p> <p>Location: Palma, Illes Balears, Spain</p> <p>Presentation title: Insights on the EU pharmaceutical regulation reform proposal</p> <p>What was your presentation about? Summary of the proposed EU regulation reform and providing some insights.</p> <p>Authors: Mireia Jofre-Bonet, George Bray and Matthias Hofer</p>
41	<p>Date: 18 September 2023</p> <p>Presenter: Mireia Jofre-Bonet</p> <p><b>Event: VIII Expert Programme in Health Policy and Pharmacoeconomics</b></p> <p>Location: Palma, Illes Balears, Spain</p> <p>Presentation title: Latest Changes to HTA in the UK</p> <p>What was your presentation about? Summary of the recent changes in the regulatory environment in the UK, including NICE Methods and Processes' review, VPAS and trends post Brexit.</p> <p>Authors: Mireia Jofre-Bonet, George Bray and Matthias Hofer</p>
42	<p>Date: 20 September 2023</p> <p>Presenter: Jake Hitch</p> <p><b>Event: EuroQol Plenary Meeting</b></p>

	<p>Location: Rome, Italy</p> <p>Presentation title: The influence of perspective on the valuation of EQ-5D-Y-3L: a comparison of value sets derived using the online personal utility functions (OPUF) tool</p> <p>Authors: Jake Hitch, Gayathri Kumar, Paul Schneider, Nancy Devlin, Koonal Shah, David Mott</p>
43	<p>Date: 20 September 2023</p> <p>Presenter: David Mott</p> <p><b>Event: EuroQol Plenary Meeting</b></p> <p>Location: Rome, Italy</p> <p>Presentation title: Valuing EQ-5D-Y-3L using the online personal utility functions (OPUF) tool: a feasibility and comparison study</p> <p>Authors: David Mott, Jake Hitch, Gayathri Kumar, Nancy Devlin, Koonal Shah, Paul Schneider</p>
44	<p>Date: 25th September 2023</p> <p>Presenter: Adrian Towse</p> <p><b>Event: 10th Anniversary Symposium of the Department of Health Economics, Medical University of Vienna</b></p> <p>Location: Vienna</p> <p>Presentation title: Price transparency of on-patent pharmaceuticals versus population health</p> <p>What was your presentation about? Price transparency of on-patent pharmaceuticals will reduce population health, especially in middle and low income countries. Confidential discounts will increase access and dynamic efficiency.</p> <p>Authors: Adrian Towse</p>
45	<p>Date: 26th September</p> <p>Presenter: Gayathri Kumar, Jennifer Harris, Tafi Maruta, Shaan Punia, Deborah Richards, Maleeha Sultan, Marvellous Ugoji, Andrew Croydon, Nabil Rastani</p> <p><b>Event: BNA Scholars Day</b></p> <p>Location: Goldings House</p> <p>Presentation title: Careers, skills and roles - panel discussion</p>
46	<p>Date: October 5<sup>th</sup> 2023</p> <p>Presenter: Lotte Steuten</p> <p><b>Event: CIRS workshop</b></p> <p>Presentation title: Next-Gen Therapies Need Next-Gen HTA</p> <p>Topic: HTA of ATMPs and C&amp;G therapies</p> <p>Location: Weybridge, UK</p> <p>Authors: Steuten L.</p>
47	<p>Date: 12th October 2023</p> <p>Presenter: Chris Sampson</p> <p><b>Event: NIHR Oxford BRC &amp; Oxford Health BRC Symposium.</b> Making the economic case to NICE for new health technologies</p> <p>Location: University of Oxford</p> <p>Presentation title: Sleepio: A recent Oxford BRC economic case study</p> <p>What was your presentation about? Describing our projects relating to the evaluation and NICE assessment of Sleepio.</p> <p>Authors: Chris Sampson</p>

48	<p>Date: 18th October 2023  Presenter: Adrian Towse  <b>Event: Centre for Health Economics (CHE) 40th Anniversary Policy Forum.</b> Location: University of York, York.  Presentation title: How much should we pay for innovation? A response to the CHE research team supporting Woods et al. (2021) and Woods et al. (2022)  What was your presentation about? Critique of presentation by Beth Woods of two papers she co-authored. I argued the case for Value-based Differential Pricing and the dangers of getting too little innovation from a pricing rule based on an estimation of an aggregate elasticity of R&amp;D supply response.  Authors: Adrian Towse</p>
49	<p>3<sup>rd</sup> November 2023  Presenter: Lotte Steuten  <b>Event: Singapore Centre for Healthcare Innovation Meeting</b>  Location: Singapore  Presentation title: Improving healthcare services with early HTA  Topic: Sharing of EU experience on evaluation of healthcare services, capturing value patient, caregiver and society perspectives. Applying early health economic evaluation for new technologies to assess potential value.  Author: Steuten, L.</p>
50	<p>Date: 3<sup>rd</sup> November 2023  Presenter: Lotte Steuten  <b>Event: Singapore Association for Pharmaceutical Industries (SAPI) Conference</b>  Location: Singapore  Presentation Title: HTA trends in Europe and its implications to Singapore  Author: Steuten, L.</p>
51	<p>Date: 6<sup>th</sup> November 2023  Presenter: Lotte Steuten  <b>Event: J&amp;J SE-Asia Leadership Event</b>  Location: Singapore  Presentation: Precision medicine and the ISPOR value flower  Author: Steuten, L.</p>
52	<p>Date: 6<sup>th</sup> November 2023  Presenter: Lotte Steuten  <b>Event: J&amp;J SE-Asia Leadership Event</b>  Location: Singapore  Presentation: Real world data and evidence – use in AP and SEA  Author: Steuten, L.</p>
53	<p>Date: 6<sup>th</sup> November 2023  Presenter: Lotte Steuten</p>

	<p><b>Event: J&amp;J SE-Asia Leadership Event</b>  Location: Singapore  Presentation: Future of EUnetHTA and NICE with international cross-agency collaborations  Author: Steuten, L.</p>
54	<p>Date: 7<sup>th</sup> November 2023  Presenter: Lotte Steuten  <b>Event: Thailand European Association for Business and Commerce (EABC) and Pharmaceutical Working Group Managed Entry Agreement Luncheon</b>  Location: Bangkok, Thailand  Presentation: Alternative financing solutions and managed entry agreements: from international experience towards implementation.  Author: Steuten, L.</p>
56	<p>Date: 7<sup>th</sup> November 2023  Presenter: Lotte Steuten  <b>Event: College of Pharmacy Administration Thailand - Continuing Education Session</b>  Location: Bangkok, Thailand  Presentation: Value of Information 1.0 for Pharmacists  Author: Steuten, L.</p>
57	<p>Date: 7<sup>th</sup> November 2023  Presenter: Lotte Steuten  <b>Event: J&amp;J Thailand Strategic Leadership Event</b>  Location: Bangkok, Thailand  Presentation: HTA trends in Europe and its implications to Thailand: including MEA and alternatives to reimbursement  Author: Steuten, L.</p>
58	<p>Date: 8<sup>th</sup> November 2023  Presenter: Lotte Steuten  <b>Event: Vietnam Health Insurance Department – closed door meeting with health department officials</b>  Location: Hanoi, Vietnam  Presentation: Alternatives to cost/ QALY and broader recognition of value  Author: Steuten, L.</p>
59	<p>Date: 8<sup>th</sup> Nov 2023  Presenter: Lotte Steuten  <b>Event: Pharma Group Health Financing Leadership Dinner Meeting</b>  Location: Hanoi, Vietnam  Presentation: Learnings and experiences from Europe on Managed Entry Agreements  Author: Steuten, L.</p>
60	<p>Date: 8th November 2023  Presenter: Nadine Henderson</p>

	<p><b>Event: Parliamentary Roundtable: Hidradenitis Suppurativa</b>  Location: Portcullis House, Westminster  Overview of OHE report "The burden of hidradenitis suppurativa on individuals, the NHS and society"  Theakston C, Henderson N, Skedgel C</p>
61	<p>Date: 9<sup>th</sup> November 2023  Presenter: Lotte Steuten  <b>Event: Asian Federation for Pharmaceutical Sciences Conference</b>  Location: Hanoi, Vietnam  Presentation: Alternatives to cost / QALY economic evaluations for middle income markets  Author: Steuten, L.</p>
62	<p>Date: 9<sup>th</sup> November 2023  Presenter: Lotte Steuten  <b>Event: The Philippine Health Technology Assessment Council (HTAC) – public lecture series</b>  Location: Philippines  Presentation: Sharing of practices in other countries on how HTA impacts access to innovative products  Presentation: Author: Steuten, L.</p>
63	<p>Date: 9<sup>th</sup> November 2023  Presenter: Lotte Steuten  <b>Event: The Philippine Health Technology Assessment Unit (HTAU) – internal educational series</b>  Location: Philippines  Presentation: Strengths and limitations of Cost/QALY threshold in a country like the Philippines  Author: Steuten, L.</p>
64	<p>Date: 10<sup>th</sup> November 2023  Presenter: Amanda Cole  <b>Event: 2023 International HTA Workshop</b>  Location: Taipei, Taiwan  Two Presentations: "Accelerating access to innovative medicine by using RWE" and "The funding for early access to innovative medicines"  In this invited speaker session, organised by Novartis and attended by key Government officials in Taiwan, including the Director General of the National Health Insurance Administration (NHIA), officials from Center for Drug Evaluation, and the Taiwanese FDA, myself along with one other Australian speaker shared our experience through presentations and a closed door question and answer session. My talks focused on RWE and its role in accelerating decision-making, as well as the experience of the Cancer Drugs Fund and the Innovative Medicines Fund in the UK.  Author: Amanda Cole</p>
65	<p>Date 12<sup>th</sup> November 2023  Presenter: Lotte Steuten  <b>Event: ISPOR Europe 2023</b>  Location: Copenhagen</p>

	<p>Presentation title: Short Course afternoon session : Early Health Technology Assessment</p> <p>Lotte and other faculty members provided an intermediate level course is for industry, researchers, advisory, regulatory, and funding agencies, governments, payers, clinicians, patients, and others who have a stake in improving care and services. The course focuses on Health Technology Assessment (HTA) concepts and methodologies in the early stages of product development (ie, early HTA). The research and development of a new medical technology is generally an expensive process; information about the potential clinical impact of a product—and its adoption and implementation into practice—at an early stage can justify the investment and guide further decision making all along the line. A major challenge is how to generate this information when no or only limited data is available.</p> <p>FACULTY MEMBERS; Janet Bouttell, MSc, PhD, University of Glasgow  Sara Graziadio, PhD, York Health Economics Consortium,  Janneke Grutters, PhD Radboud Institute for Health Sciences,  Ties Hoomans, PhD London School of Economics and Political Science and  Lotte Steuten,</p>
66	<p>Date 13<sup>th</sup> November 2023</p> <p>Presenter: Hania El Banhawi</p> <p><b>Event: ISPOR Europe 2023</b></p> <p>Location: Copenhagen</p> <p>Presentation title: The Socio-Economic Value of Adult Immunisation</p> <p>What was your presentation about? An assessmeny and synthesis of the evidence for the broad, socio-economic value of adult immunisation programmes, focusing on influenza, pneumococcal, herpes zoster (HZ), and respiratory syncytial virus (RSV) programmes in ten countries.</p> <p>Authors: Hania El Banhawi, Eleanor Bell, Sulayman Chowdhury, Simon Brassel, Fabian Alvarez, Goran Bencina, Raymond Farkouh, Kinga Meszaros, Lotte Steuten</p>
67	<p>Date 13<sup>th</sup> November 2023</p> <p>Presenter: Lotte Steuten</p> <p><b>Event: ISPOR Europe 2023</b></p> <p>Location: Copenhagen</p> <p>Presentation title: Issues Regarding Pricing and Access to Gene and Advanced Therapy Medicinal Products</p> <p>OVERVIEW: Dr. Campbell w moderates a session with Panelists discussing the issues and solutions to this problem. Dr. Steuten provided an overview of recent and recommended changes to HTA methodologies and evidence-generation activities in nine European countries, plus Canada and Australia, that would enable the full value of ATMPs and gene therapies to be captured in HTA. She will illustrate these activities using examples of best practices internationally. Dr. Briggs will consider the evaluation of ATMPs within a fixed-threshold system such as the UK, including issues of budget impact and possible risk-sharing arrangements. Dr. Basu will discuss the role of budget impact in assessing value-based prices for gene therapies, present a case analysis of pricing gene therapy for sickle cell disease in the US, and demonstrate what different US state Medicaid programs can do to absorb the initial budget impact.</p> <p>MODERATOR Jon Campbell, PhD, National Pharmaceutical Council, Washington, DC,  PANELISTS Anirban Basu, PhD, MS University of Washington, Seattle, WA, USA  Andrew Briggs, DPhil, London School of Hygiene and Tropical Medicine, London  Lotte Steuten, PhD, Office of Health Economics, London,</p>
68	<p>Date: 14<sup>th</sup> November 2023</p> <p>Presenter Nadine Henderson &amp; Grace Hampson</p> <p><b>Event: ISPOR Europe 2023</b></p>

	<p>Panel: Charting a Greener Future Decarbonisation of the pharmaceutical industry Henderson N</p>
69	<p>Date: 14th November 2023 Presenter: Nadine Henderson <b>Event: ISPOR Europe 2023</b> Poster presentation: HTA of Multiple Myeloma Therapies: Value recognition and demonstration challenges Henderson N, Neri M, Gallagher J, Steuten L</p>
70	<p>Date 14th November 2023 Presenter: Lotte Steuten <b>Event: ISPOR Europe 2023</b> Location: Copenhagen Presentation title: Pathways to ISPOR Leadership Become an ISPOR Leader! Lotte provided insights into the pathways to ISPOR leadership through shared stories, experiences, and discussion.</p>
71	<p>Date: 14<sup>th</sup> November 2023 Presenter: Simon Brassel (Moderator) &amp; Grace Hampson <b>Event: ISPOR Europe 2023</b> Location: Copenhagen Presentation title: An Eye for the Future: Does an Interdisciplinary View Help Improve Discounting Approaches for Curative Gene Therapies? What was your presentation about? Moderating a panel session on discounting approaches relevant to gene therapies and what health economics might be able to learn from environmental economics. Authors: n/a</p>
72	<p>Date: 14th November 2023 Presenter: Patricia Cubi-Molla <b>Event: ISPOR Europe 2023</b> Location: Copenhagen, Denmark Presentation title: Is it time to update the discount rate in the Slovak Republic? What was your presentation about? The suggested discount rate used for HTA in Slovakia is 3.3% (which should replace the existing one 5%) Authors: Hitch, J., Berdud, M., Cubi-Molla, P., Garau, M., Towse, A.</p>
73	<p>Date: 15th November 2023 Presenter: Simon Brassel (Grace Hampson) <b>Event: ISPOR Europe 2023</b> Location: Copenhagen Presentation title: Is Stedi Steady? an Exploration of the Uncertainties Underlying the Quantification of the Broader Value of Antibiotics What was your presentation about? The uncertainties associated with quantifying the STEDI value profile of antibiotics.</p>



	Authors: Simon Brassel
74	<p>Date: 14th November 2023  Presenter: Grace Hampson  <b>Event: ISPOR Europe 2023</b>  Location: Copenhagen  Presentation title: What Should Value Assessment of New Antibiotics Look like in the Context of Pull Incentives? the How, What, and Where Next for Antimicrobial Resistance and Health Technology Assessment.  Authors: n/a</p>
75	<p>Date: 15th November 2023  Presenter: Sian Besley  <b>Event: ISPOR Europe 2023</b>  Location: The Bella Centre, Copenhagen  Presentation title: The Race to Improve Health Technology Assessment of Gene Therapies: Which Countries are Embracing Recommendations?  What was your presentation about? In June 2022 we published a report exploring the challenges of health technology assessment (HTA) of gene therapies. Based on an expert roundtable, we developed 6 recommendations. This poster discussed work published in a report in September 2023 in which we explored the extent to which our recommendations are being achieved in nine European countries, Australia and Canada.  Poster Authors: Sian Besley, Nadine Henderson, Matthew Napier, Amanda Cole, Grace Hampson, Lauren Diamond, Safiyya Gassman, David Fortier, Ruth Kim</p>
76	<p>Date: 15th November 2023  Presenter: Mikel Berdud and Graham Cookson  <b>Event: ISPOR Europe 2023</b>  Location: Copenhagen, Denmark  Presentation title: Pricing pharmaceuticals for the common good: is value-based pricing still the right solution?  What was your presentation about? it discussed what is the common good in the context of markets for innovative pharmaceuticals. I defined it as the triple win i.e., access to patients, sustainability for health systems and incentives for innovators. Then it defined the market failure for pharmaceutical innovation and the role of pricing in, fixing the market failure and achieving the triple win to set the question about whether VBP is still the right solution for that.  Authors: Mikel Berdud; Graham Cookson</p>
78	<p>Date: 16th November 2023  Presenter: Chris Sampson  <b>Event: MSc Translational Health Sciences</b>  Location: Oxford  Presentation title: HTA decision-making and the NICE threshold  What was your presentation about? Lecture  Authors: Chris Sampson, Lotte Steuten</p>
79	<p>Date: 16<sup>th</sup> November 2023  Presenter – Graham Cookson  <b>Event: UCL Global Business School for health</b></p>

	<p>Balancing innovation and affordability in pharmaceutical markets: understanding the impact of the US government's Inflation Reduction Act Graham presented to an audience (about 50/50) of faculty and PhD/DBA researchers. Authors Graham</p>
80	<p>Date: 27th November 2023 Presenter: Chris Sampson <b>Event: MSc Mental Health Economics</b> Location: London Presentation title: Topic 7: Government intervention and policies What was your presentation about? Lecture Authors: Chris Sampson</p>
81	<p>Date: 5th December 2023 Presenter: Mireia Jofre-Bonet <b>Event: Invited Lecture and Meeting with the Convergence Science Senior Team</b> Location: Convergence Science Centre, Institute for Cancer Research, Imperial College Presentation title: Health Economics and Early HTA What was your presentation about? It was a brief introduction to NICE and HTA.</p>
82	<p>Date: 6<sup>th</sup> December 2023 Presenter: Lotte Steuten <b>Event: The Silver Economy 2023 meeting of the Coalition for Aging and the United Nations</b> Location: New York Presentation: the socio-economic value of adult immunization programmes in an aging society Authors: El-Banhawi H., Bell, E., Neri M., Brassel S., Chowdhury S., Besley S., Steuten L.</p>
83	<p>Date: 7th December 2023 Presenter: Patricia Cubi-Molla <b>Event: Guest lecture for MSc Economic Evaluation and MSc Health Economics</b> Location: City, University of London (UK) Presentation title: On thresholds, HTA reforms, and resource allocation What was your presentation about? We reviewed the main changes in NICE methods' guidelines, with discussion on modifiers; explored changes in HTA methods &amp; processes (M&amp;P) across jurisdictions; and different values for health across public sectors in UK and five other countries. Authors: Patricia Cubi-Molla</p>
84	<p>Date: 10 December 2023 Presenter: David Mott <b>Event: ASH Annual Meeting</b> Location: San Diego, USA Presentation title: Understanding Relapsed/Refractory Acute Leukemia Patients' Treatment Preferences: Insights from Qualitative Research Authors: Zack Pemberton-Whiteley, Samantha Nier, David Mott, Chris Skedgel, Jake Hitch</p>



## Citations over time

NO.	JOURNAL REFERENCE	SOURCES OF FINANCIAL SUPPORT	NUMBER OF CITATIONS (AS OF OCT 23) <sup>1</sup>	SJR INDICATOR (2022) <sup>2</sup>	ABS JOURNAL RANKING (2021) <sup>3</sup>
<b>2022</b>					
1	<b>Bell, E., Brassel, S., Oliver, E., Schirmacher, H., Arnetorp, S., Berg, K., Darroch-Thompson, D., Polja-Hutchison, P., Mungall, B., Carroll, S., Postma, M. and Steuten, L.</b> , 2022. Estimates of the Global Burden of COVID-19 and the Value of Broad and Equitable Access to COVID-19 Vaccines. <i>Vaccines</i> . DOI: <a href="https://doi.org/10.3390/vaccines10081320">10.3390/vaccines10081320</a>	Contract Funded (AstraZeneca)	9	1.655	N/A
2	<b>Bell, E., Neri, M., &amp; Steuten, L.</b> 2022. Towards a Broader Assessment of Value in Vaccines: The BRAVE Way Forward. <i>Applied Health Economics and health policy</i> . DOI: <a href="https://doi.org/10.1007/s40258-021-00683">10.1007/s40258-021-00683</a>	Funded Research (Pfizer)	17	N/A	N/A
3	<b>Brassel, S., Neri, M., Schirmacher, H., Steuten, L.</b> , 2022. The Value of Vaccines in Maintaining Health System Capacity in England. <i>Value in Health</i> . DOI: <a href="https://doi.org/10.1016/j.jval.2022.06.018">10.1016/j.jval.2022.06.018</a>	Consulting (ABPI)	5	1.414	N/A
4	El-Shal, A., <b>Cubi-Molla, P.</b> and <b>Jofre-Bonet, M.</b> , 2022. Discontinuation of performance-based financing in primary health care: impact on family planning and maternal and child health. <i>International Journal of Health Economics and Management</i> . DOI: <a href="https://doi.org/10.1007/s10754-022-09333-w">10.1007/s10754-022-09333-w</a>	Unfunded	1	0.535	2
5	Fernandes, S., Pinto, M., Barros, L., Lopes Moreira, M.E., Velho Barreto de Araújo, T., Maciel Lyra, T., Valongueiro, S., <b>Jofre-Bonet, M.</b> , <b>Kuper, H.</b> 2022. The economic burden of Congenital Zika Syndrome in Brazil: overview at 5 and 10 years. <i>BMJ Global Health</i> . DOI: <a href="https://doi.org/10.1136/bmjgh-2022-008784">10.1136/bmjgh-2022-008784</a>	Unfunded	2	2.376	N/A
6	Hernandez-Villafuerte, K., <b>Zamora, B.</b> , Feng, Y. <b>Towse, A.</b> et al. 2022. Estimating health system opportunity costs: the role of non-linearities and inefficiency. <i>Cost Effectiveness and Resource Allocation</i> . DOI: <a href="https://doi.org/10.1186/s12962-022-00391">10.1186/s12962-022-00391</a>	ABPI	1	0.530	N/A
7	Horgan, D., <b>Borisch, B.</b> , Cattaneo, I., Caulfield, M., Chiti, A., Chomienne, C., <b>Cole, A.</b> , et al., 2022. Factors Affecting Citizen Trust and Public Engagement Relating to the Generation and Use of Real-World Evidence in Healthcare. <i>International Journal of Environmental Research and Public Health</i> . DOI: <a href="https://doi.org/10.3390/ijerph19031674">10.3390/ijerph19031674</a>		5	0.828	N/A
8	Husereau, D., <b>Drummond, M.</b> , <b>Augustovski, F.</b> , de Bekker-Grob, E., Briggs, A. H., Carswell, C., et al as part of the CHEERS 2022 ISPOR Good Research Practices Task Force 2022., Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. <i>European Journal of Health Economics</i> . (Epub ahead of print). DOI: <a href="https://doi.org/10.1007/s10198-021-01426-6">10.1007/s10198-021-01426-6</a> .	Unfunded	221	1.042	2
9	Husereau, D.; <b>Steuten, L.</b> ; Muthu, V.; Thomas, D.M.; Spinner, D.S.; Ivany, C.; Mengel, M.; Sheffield, B.; Yip, S.; Jacobs, P.; Sullivan, T. 2022. Effective and Efficient Delivery of Genome-Based Testing- What Conditions Are Necessary for Health System Readiness? <i>Healthcare</i> 2022. DOI: <a href="https://doi.org/10.3390/healthcare10102086">10.3390/healthcare10102086</a>	Amgen Canada, Inc.; AstraZeneca Canada Inc.; Eli Lilly Canada, Inc.; GSK Canada Inc.; Hoffmann-La Roche Canada, Inc. (Diagnostics Division); Janssen (J&J) Canada Inc.; Pfizer Canada Inc.; Thermo Fisher Scientific (Canada)	3	0.786	N/A
10	<b>Kourouklis, D., Berdud, M., Jofre-Bonet, M.</b> and <b>Towse, A.</b> , 2022. Alternative funding models for medical innovation: the role of product development partnerships in product innovation for infectious diseases. <i>Applied Economics Letters</i> . DOI: <a href="https://doi.org/10.1080/13504851.2022.2095335">10.1080/13504851.2022.2095335</a>	Core research grant	0	0.450	2

11	<b>Kourouklis, D.</b> and Gandjour, A., 2022. Pharmaceutical Spending and Early-Stage Innovation in EU countries. <i>Industry and Innovation</i> . DOI: <a href="https://doi.org/10.1080/13662716.2021.2021864">10.1080/13662716.2021.2021864</a>	Unfunded	1	1.323	3
12	<b>Kourouklis, D., Sampson, C., Berdud, M. and Skedgel, C.</b> 2022. Building Cost-Effectiveness Thresholds for the Future. <i>Value &amp; Outcomes Spotlight</i> . DOI: <a href="https://doi.org/10.1007/s10198-021-01426-6">10.1007/s10198-021-01426-6</a>	Contract Funded (ABPI)	1	N/A	N/A
13	Kreimeier, S., <b>Mott, D.</b> , Ludwig, K., Greiner, W., & IMPACT HTA HRQoL Group. 2022. EQ-5D-Y Value Set for Germany. <i>Economics</i> . DOI: <a href="https://doi.org/10.1007/s40273-022-01143-9">10.1007/s40273-022-01143-9</a>	Funded research (EuroQol)	19	1.389	2
14	Mateo, J., <b>Steuten, L.</b> , Aftimos, P., André, F., Davies, M., Garralda, E., Geissler, J., Husereau, D., Martinez-Lopez, I., Normanno, N., Reis-Filho, J., Stefani, S., Thomas, D., Westphalen, B., & Voest, E. 2022. Delivering Precision Oncology to Patients with Cancer. <i>Nature Medicine</i> . DOI: <a href="https://doi.org/10.1038/s41591-022-01717-2">10.1038/s41591-022-01717-2</a>	Unfunded	103	24.687	N/A
15	<b>Mott, D. J.</b> , Devlin, N. J., Kreimeier, S., Norman, R., Shah, K. K., & Rivero-Arias, O. 2022. Analytical Considerations When Anchoring Discrete Choice Experiment Values Using Composite Time Trade-Off Data: The Case of EQ-5D-Y-3L. <i>PharmacoEconomics</i> . DOI: <a href="https://doi.org/10.1007/s40273-022-01214-x">10.1007/s40273-022-01214-x</a>	Funded research (EuroQol)	3	1.389	2
16	<b>Mott, D.</b> , Ternent, L., & Vale, L. 2022. Do preferences differ based on respondent experience of a health issue and its treatment? A case study using a public health intervention. <i>The European Journal of Health Economics</i> . DOI: <a href="https://doi.org/10.1007/s10198-022-01482-">10.1007/s10198-022-01482-</a>	Funded research (Health Foundation)	4	1.042	2
17	Mulhern, B.J., <b>Sampson, C.</b> , Haywood, P., Addo, R., Page, K., <b>Mott, D.</b> , Shah, K., Janssen, M.F. and <b>Herdman, M.</b> , 2022. Criteria for Developing, Assessing and Selecting Candidate EQ-5D Bolt-Ons. <i>Quality of Life Research</i> . DOI: <a href="https://doi.org/10.1007/s11136-022-03138-7">10.1007/s11136-022-03138-7</a>	Funded research (EuroQol)	4	3.44	4.388
18	Pouwels, X.G.L.V., <b>Sampson, C.J.</b> , and Arnold, R.J.G., 2022. Opportunities and Barriers to the Development and Use of Open Source Health Economic Models: A Survey. <i>Value in Health</i> . DOI: <a href="https://doi.org/10.1016/j.jval.2021.10.001">10.1016/j.jval.2021.10.001</a>	Unfunded	8	1.414	N/A
19	Ramos-Goñi, J. M., Estévez-Carrillo, A., Rivero-Arias, O., Rowen, D., <b>Mott, D.</b> , Shah, K., & Oppe, M. 2022. Does Changing the Age of a Child to be Considered in 3-Level Version of EQ-5D-Y Discrete Choice Experiment-Based Valuation Studies Affect Health Preferences? <i>Value in Health</i> . DOI: <a href="https://doi.org/10.1016/j.jval.2022.03.001">10.1016/j.jval.2022.03.001</a>	Funded research (EuroQol)	9	1.414	N/A
20	<b>Rodes-Sanchez, M.</b> , Spencer, J., Tantri, A., Mitrovich, R., Rachev, B., Sharma, I., <b>Towse, A.</b> , <b>Steuten, L.</b> 2022. Working Towards a Sustainable, Healthy Market for Vaccines: A Framework to Support Evidence-Based Policymaking. <i>Vaccine</i> 2022. DOI: <a href="https://doi.org/10.1016/j.vaccine.2022.05.054">10.1016/j.vaccine.2022.05.054</a>	Contract Funded (Merck Sharp & Dohme)	0	1.493	N/A
21	<b>Sampson, C.</b> , Zamora, B., Watson, S., Cairns, J., Chalkidou, K., <b>Cubi-Molla, P.</b> , Devlin, N., García-Lorenzo, B., Hughes, D.A., Leech, A.A. and Towse, A., 2022. Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy. <i>Applied Health Economics and Health Policy</i> . DOI: <a href="https://doi.org/10.1007/s40258-022-00730-3">10.1007/s40258-022-00730-3</a>	Contract Funded (ABPI)	9	1.017	N/A
22	<b>Sampson, C.</b> NICE and the EQ-5D-5L: Ten Years Trouble. <i>PharmacoEconomics Open</i> 6, 5–8 (2022). <a href="https://doi.org/10.1007/s41669-021-00315-1">https://doi.org/10.1007/s41669-021-00315-1</a>	Unfunded	0	0.646	2
23	<b>Skedgel, C., Henderson, N., Towse, A., Mott, D.</b> , & Green, C. 2022. Considering Severity in Health Technology Assessment: Can We Do Better? <i>Value in Health</i> . DOI: <a href="https://doi.org/10.1016/j.jval.2022.03.001">10.1016/j.jval.2022.03.001</a>	Contract Funded (Biogen)	11	1.414	N/A
24	<b>Towse, A.</b> 2022. Real Option Value: Should We Opt in or out? Commentary. <i>Value in Health</i> . DOI: <a href="https://doi.org/10.1016/j.jval.2022.09.004">10.1016/j.jval.2022.09.004</a>	Core research grant	0	1.414	N/A

25	<b>Towse, A.</b> and Silverman Bonnifield, R. 2022. An Ambitious USG Advanced Commitment for Subscription-Based Purchasing of Novel Antimicrobials and Its Expected Return on Investment. <i>CGD Policy Paper 277</i> . Washington, DC: Center for Global Development. <a href="https://www.cgdev.org/publication/ambitious-usg-advanced-commitment-subscription-based-purchasing-novel-antimicrobials">https://www.cgdev.org/publication/ambitious-usg-advanced-commitment-subscription-based-purchasing-novel-antimicrobials</a>	Unfunded	6	N/A	N/A
26	Treibich, C., <b>Bell, E.</b> , Blanc, E., Lepine, A., 2022. From a drought to HIV: An analysis of the effect of droughts on transactional sex and sexually transmitted infections in Malawi. <i>SSM - Population Health</i> . DOI: <a href="https://doi.org/10.1016/j.ssmph.2022.101221">10.1016/j.ssmph.2022.101221</a>	Unfunded	0	1.785	N/A
27	Vass, C., Boeri, M., Karim, S., Marshall, D., Craig, B., Ho, K.-A., <b>Mott, D.</b> , Ngorsuraches, S., Badawy, S. M., Mühlbacher, A., Gonzalez, J. M., & Heidenreich, S. 2022. Accounting for Preference Heterogeneity in Discrete-Choice Experiments: An ISPOR Special Interest Group Report. <i>Value in Health</i> . DOI: <a href="https://doi.org/10.1016/j.jval.2022.01.012">10.1016/j.jval.2022.01.012</a>	Core research grant	15	1.414	N/A
28	Yaman, F., <b>Cubi-Molla, P.</b> and Plagnol, A.C., 2022. Why do immigrants become less happy? Explanations for the decrease in life satisfaction of immigrants in Germany over time. <i>Migration Studies</i> . DOI: <a href="https://doi.org/10.1093/migration/mnac034">10.1093/migration/mnac034</a>	Unfunded	2	0.531	N/A

Journal reference	number of citations (As of oct 23) <sup>1</sup>	Sjr INDICATOR (2022) <sup>2</sup>	ABS Journal RANKING (2021) <sup>3</sup>	
<b>2021</b>				
1	Bogosian, A, Hurt, C.S, Hindle, J.V, McCracken, L.M, Vasconcelos e Sa, D.A., Axell, S, Tapper, K, Stevens, J, Hirani, P.S, Salhab, M, Ye, W. and <b>Cubi-Molla, P.</b> (2021) Acceptability and Feasibility of a Mindfulness Intervention Delivered via Videoconferencing for People With Parkinson's. <i>Journal of Geriatric Psychiatry and Neurology</i> . DOI: <a href="https://doi.org/10.1177/08919887209881901">10.1177/08919887209881901</a>	12	0.808	N/A
2	El-Shal, A, <b>Cubi-Molla, P.</b> and <b>Jofre-Bonet, M.</b> (2021) Accreditation as a quality-improving policy tool: family planning, maternal health, and child health in Egypt. <i>The European Journal of Health Economics</i> . DOI: <a href="https://doi.org/10.1007/s10198-020-01240-6">10.1007/s10198-020-01240-6</a>	7	1.042	2
3	<b>Sampson, C, Zhang, K.,</b> Parkin, D. and <b>Hampson, G.</b> (2021b) Exclusive human milk diet for very preterm babies in England: protocol for a cost-effectiveness and budget impact analysis. <i>F1000Research</i> . DOI: <a href="https://doi.org/10.12688/f1000research.22450.1">10.12688/f1000research.22450.1</a>	2	N/A	N/A
4	<b>Kourouklis, D.,</b> 2021. Public subsidies for R&D and public sector pharmaceutical innovation. <i>Applied Economics</i> , 53(32), pp.3759–3777. DOI: <a href="https://doi.org/10.1080/00036846.2021.1885614">10.1080/00036846.2021.1885614</a> .	10	0.450	2
5	<b>Latimer, N.R., Towse, A.,</b> and <b>Henshall, C</b> (2021) Not cost-effective at zero price: valuing and paying for combination therapies in cancer, <i>Expert Review of Pharmacoeconomics &amp; Outcomes Research</i> DOI: <a href="https://doi.org/10.1080/14737167.2021.1879644">10.1080/14737167.2021.1879644</a>	7	N/A	N/A

6	<b>Sampson C, Firth I, Towse A.</b> (2021) Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al.: <i>Medical Decision Making</i> . DOI: <a href="https://doi.org/10.1177/0272989x20987211">10.1177/0272989x20987211</a>	2	1.262	N/A
7	<b>Skedgel C,</b> Ralphs E, Finn E, et al. (2021) Is the public supportive and willing to pay for a national assistive reproductive therapies programme? Results from a multi-country survey. <i>BMJ Open</i> , 11:e044986. DOI: <a href="https://doi.org/10.1136/bmjopen-2020-044986">10.1136/bmjopen-2020-044986</a>	6	2.867	N/A
8	<b>Mott DJ,</b> Shah KK, Ramos-Goñi JM, Devlin NJ, Rivero-Arias O. (2021) Valuing EQ-5D-Y-3L Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ? <i>Medical Decision Making</i> . DOI: <a href="https://doi.org/10.1177/0272989x21999607">10.1177/0272989x21999607</a>	41	1.262	N/A
9	Zamora B., Garrison L.P., Unuigbo A., and <b>Towse A.</b> (2021). Reconciling ACEA and MCDA: is there a way forward for measuring cost-effectiveness in the USS healthcare setting? <i>Cost Effectiveness and Resource Allocation</i> . DOI: <a href="https://doi.org/10.1186/s12962-021-00266-8">10.1186/s12962-021-00266-8</a>	6	0.828	N/A
10	Pearson S.D., <b>Towse A.</b> , Lowe M., Segel C.S., and Henshall C. (2021) Cornerstones of 'fair' drug coverage: appropriate cost sharing and utilisation management policies for pharmaceuticals. <i>Journal of Comparative Effectiveness Research</i> . DOI: <a href="https://doi.org/10.2217/ceer-2021-0027">10.2217/ceer-2021-0027</a>	10	0.575	N/A
11	<b>Brassel, S, Neri, M, O'Neill, P. and Steuten, L.</b> (2021) Realising the Broader Value of Vaccines in the UK. <i>Vaccine: X</i> , p.100096. DOI: <a href="https://doi.org/10.1016/j.jvacx.2021.100096">10.1016/j.jvacx.2021.100096</a>	10	1.655	N/A
12	<b>Jofre-Bonet, M.</b> (2021) Invited Tribune: COVID-19 and vaccines: Learning by Doing- Estudios sobre la Economía Española, 2021/04 Aspectos Económicos de la crisis del COVID-19. Boletín de Seguimiento no. 10. Fundación de Estudios de Economía Aplicada (FEDEA). <a href="https://documentos.fedea.net/pubs/eee/eee2021-14.pdf">https://documentos.fedea.net/pubs/eee/eee2021-14.pdf</a>	N/A	N/A	N/A
13	<b>Jofre-Bonet, M.</b> (2021) About economic research that does not involve money. <i>Societat Catalana d'Economia - 5centims.cat</i> . <a href="https://www.5centims.cat/sobre-la-recerca-economica-que-no-va-de-diners/">https://www.5centims.cat/sobre-la-recerca-economica-que-no-va-de-diners/</a>	N/A	N/A	N/A
14	Latimer N, Pollard P, <b>Towse A,</b> Henshall C, Sansom L, Ward R, Bruce A, and Deakin C. (2021) Challenges in valuing and paying for combination regimens in oncology: reporting the perspectives of a multistakeholder, international workshop. <i>BMC Health Services Research</i> 21:412. DOI: <a href="https://doi.org/10.1186/s12913-021-06425-0">10.1186/s12913-021-06425-0</a>	13	0.964	3
15	<b>Towse A.,</b> Chalkidou K., <b>Firth I.,</b> Kettler H., and Silverman R. (2021) How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine? <i>Value in Health</i> . DOI: <a href="https://doi.org/10.1016/j.jval.2020.12.008">https://doi.org/10.1016/j.jval.2020.12.008</a>	16	1.414	N/A
16	<b>Mott, D.J.,</b> Leslie, I., Shah, K., Rowell, J. & Scheuer, N. (2021) Impact of Including Carer Information in Time Trade-Off Tasks: Results from a Pilot Study. <i>PharmacoEconomics - open</i> . DOI: <a href="https://doi.org/10.1007/s41669-021-00270-x">10.1007/s41669-021-00270-x</a>	0	N/A	N/A
17	Zhang K, <b>Kumar G, Skedgel C.</b> (2021) Towards a New Understanding of Unmet Medical Need. <i>Applied Health Economics and Health Policy</i> . DOI: <a href="https://doi.org/10.1007/s40258-021-00655-3">10.1007/s40258-021-00655-3</a>	7	1.017	N/A
18	<b>Cubi-Molla P,</b> Buxton M, Devlin N. (2021) Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere? <i>Applied Health Economics and Health Policy</i> . Jun 9:1-0. DOI: <a href="https://doi.org/10.1007/s40258-021-00648-2">10.1007/s40258-021-00648-2</a>	11	1.017	N/A

19	<b>Neri, M., Cubi-Molla, P. &amp; Cookson, G.</b> (2021) Approaches to Measuring Efficiency in Primary Care: A Systematic Literature Review. <i>Applied Health Economics and Health Policy</i> . DOI: <a href="https://doi.org/10.1007/s40258-021-00669-x">10.1007/s40258-021-00669-x</a>	5	1.017	N/A
20	<b>El-Shal, A., Cubi-Molla, P. and Jofre-Bonet, M.</b> (2021) Are user fees in health care always evil? Evidence from family planning, maternal, and child health services. <i>Economic Analysis and Policy</i> . DOI: <a href="https://doi.org/10.1016/j.eap.2021.08.009">10.1016/j.eap.2021.08.009</a>	2	1.098	1
21	<b>Bell, E., Neri, M, and Steuten. L.</b> (2021) Towards a Broader Assessment of Value in Vaccines: The BRAVE Way Forward. <i>Applied Health Economics and Health Policy</i> . 23:1–13. DOI: <a href="https://doi.org/10.1007/s40258-021-00683-z">10.1007/s40258-021-00683-z</a> .	17	1.017	N/A
22	Payne, H., Robinson, A., Rappe, B., Hilman, S., De Giorgi, U., Joniau, S., Bordonaro, R., Mallick, S., Dourthe, L.-M., Flores, M. M., Gumà, J., Baron, B., Duran, A., Pranzo, A., Serikoff, A., <b>Mott, D.J.</b> , Herdman, M., Pavesi, M., & De Santis, M. (2021) A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE. <i>International Journal of Cancer</i> . DOI: <a href="https://doi.org/10.1002/ijc.33845">10.1002/ijc.33845</a>	11	2.259	N/A
23	Flood, C., Behn, N., Marshall, J., Simpson, A., Northcott, S., Thomas, S., Goldsmith, K., McVicker, S., <b>Jofre-Bonet, M.</b> and Hilari, K., 2021. A pilot economic evaluation of a feasibility trial for Supporting wellbeing through PEer-Befriending (SUPERB) for post-stroke aphasia. <i>Clinical Rehabilitation</i> . DOI: <a href="https://doi.org/10.1177/02692155211063554">10.1177/02692155211063554</a>	0	0.874	N/A
24	<b>Bajre MK, Towse A, Stainthorpe A, Hart J.,</b> 2021. Results from an Early Economic Evaluation of the use of A Novel Point of Care Device for Diagnosis of Suspected Acute Coronary Syndrome Patient Within an Emergency Department in the National Health Service in England. <i>Cardiology and Cardiovascular Medicine</i> . DOI: <a href="https://doi.org/10.26502/fccm.92920228">10.26502/fccm.92920228</a>	0	N/A	N/A
25	<b>Sampson, C, Bell, E., Cole, A.,</b> Miller, C.B., Marriott, T., Williams, M. and Rose, J., 2021. Digital cognitive behavioural therapy for insomnia and primary care costs in England: an interrupted time series analysis. <i>BJGP Open</i> . DOI: <a href="https://doi.org/10.3399/BJGPO.2021.0146">10.3399/BJGPO.2021.0146</a>	10	N/A	N/A
26	<b>Skedgel, C.,</b> Ralphs, E., Finn, E., Markert, M., Samuelsen, C. & Whitty, J. 2021. How Do People with Experience of Infertility Value Different Aspects of Assistive Reproductive Therapy? <i>The Patient – Patient Centred Outcomes Research</i> . DOI: <a href="https://doi.org/10.1007/s40271-021-00563-7">10.1007/s40271-021-00563-7</a>	5	N/A	N/A
27	<b>Skedgel, C.</b> 2021. Dramatic Innovations in the Treatment of Spinal Muscular Atrophy, But Many Unknowns Remain. <i>Pharmacoeconomics</i> . DOI: <a href="https://doi.org/10.1007/s40273-021-01119-1">10.1007/s40273-021-01119-1</a> .	0	1.389	2
2020				
1	Fenwick E, <b>Steuten L</b> , Knies S, Ghabri S, Basu A, Murray JF, Koffijberg HE, Strong M, Sanders Schmidler GD, Rothery C. (2020) Value of Information Analysis for Research Decisions-An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. <i>Value in Health</i> , Feb;23(2):139-150. doi: <a href="https://doi.org/10.1016/j.jval.2020.01.001">10.1016/j.jval.2020.01.001</a> . PubMed PMID: 32113617.	114	1.414	N/A
2	Garrison, L., <b>Zamora, B.</b> , Li, M., and <b>Towse, A.</b> (2020). Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 26(4), pp.400-406.	24	0.760	N/A



3	<b>Herdman, M.</b> , Kerr, C., Pavesi, M., Garside, J., Lloyd, A., <b>Cubi-Molla, P.</b> and Devlin, N., (2020). Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L. <i>Journal of Patient-Reported Outcomes</i> , 4(1), pp.1-12.	6	N/A	N/A
4	Hilari, Katerina, Nicholas Behn, Jane Marshall, Alan Simpson, Shirley Thomas, Sarah Northcott, Chris Flood, <b>Mireia Jofre-Bonet</b> , et al. (2020) Adjustment with Aphasia after Stroke: Study Protocol for a Pilot Feasibility Randomised Controlled Trial for Supporting Wellbeing through PEEr Befriending (SUPERB). <i>Pilot and Feasibility Studies</i> 5, no. 1: 14. <a href="https://doi.org/10.1186/s40814-019-0397-6">https://doi.org/10.1186/s40814-019-0397-6</a> .	31	N/A	N/A
5	J Costa-Font, <b>M Jofre-Bonet</b> . (2020). Is the Intergenerational Transmission of Overweight 'Gender Assortative'? <i>Economics &amp; Human Biology</i> , 100907.	10	1.041	2
6	Lorgelly, P., Pollard, J., <b>Cubi-Molla, P.</b> , <b>Cole, A.</b> , Sim, D. and Sussex, J., (2020). Outcome-Based Payment Schemes: What Outcomes Do Patients with Cancer Value? <i>The Patient-Patient-Centered Outcomes Research</i> , pp.1-12.	11	N/A	N/A
7	<b>Mott, D.J.</b> , Chami, N. & Tervonen, T. (2020) Reporting Quality of Marginal Rates of Substitution in Discrete Choice Experiments That Elicit Patient Preferences. <i>Value in Health</i> . 23 (8), 979–984.	15	1.414	6.934
8	<b>Mott, D.J.</b> , <b>Hampson, G.</b> , Llewelyn, M.J., Mestre-Ferrandiz, J. & Hopkins, M.M. (2020) Authors' Reply to Hays: 'A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance'. <i>Applied Health Economics and Health Policy</i> . 18 (3), 459–460.	0	1.017	N/A
9	Rothery C, Strong M, Koffijberg HE, Basu A, Ghabri S, Knies S, Murray JF, Sanders Schmidler GD, <b>Steuten L</b> , Fenwick E. (2020) Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. <i>Value in Health</i> . Mar;23(3):277-286. doi: <a href="https://doi.org/10.1016/j.jval.2020.01.004">10.1016/j.jval.2020.01.004</a> . PubMed PMID: 32197720.	76	1.414	N/A
10	Shaikh, M., Del Giudice, P. and <b>Kourouklis, D.</b> , (2020). Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment. <i>Applied Health Economics and Health Policy</i> . 10.1007/s40258-020-00601-9.	16	1.017	N/A
11	DeVolder, R., Serra-Sastre, V. and <b>Zamora, B.</b> , (2020). Examining the variation across acute trusts in patient delayed discharge. <i>Health Policy</i> .	6	1.062	2
12	Chalkidou K, <b>Towse A</b> , Silverman R, <b>Garau M</b> , Ramakrishnan G. (2020). Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB. <i>BMJ Global Health</i> ; 5: e002061.	5	2.376	N/A
13	<b>Berdud M</b> , Drummond M, and <b>Towse A</b> . (2020). Establishing a reasonable price for an orphan drug. <i>Cost Effectiveness and Resource Allocation</i> <a href="https://doi.org/10.1186/s12962-020-00223-x">https://doi.org/10.1186/s12962-020-00223-x</a>	60	0.530	N/A
14	Costa-Font, J., <b>Jofre-Bonet, M.</b> , J. Legrand (2020) Vertical Transmission of Overweight: Evidence from a sample of English Adoptees, forthcoming <i>Food Policy</i> .	3	1.896	3

2019				
1	Broadbent, D., <b>Sampson, C.J.</b> , Wang, A., Howard, L., Williams, A., Howlin, S., Appelbe, <b>D.</b> , <b>Mott</b> , T., Cheyne, C., Rahni, M., Kelly, J., Collins, J., García-Fiñana, M., Stratton, I., James, M., and Harding, S. 2019. Individualised Screening for Diabetic Retinopathy: the ISDR study. Rationale, design and methodology for a randomised controlled trial comparing annual and personalised variable-interval risk-based screening. <i>BMJ Open</i> . 9(e025788). DOI: <a href="https://doi.org/10.1136/bmjopen-2018-025788">10.1136/bmjopen-2018-025788</a> .	21	2.867	N/A
2	<b>Cubi-Molla, P.</b> , <b>Shah, K.</b> , Garside, J., Herdman, M. and Devlin, N., 2019. A note on the relationship between age and health-related quality of life assessment. <i>Quality of Life Research</i> , 28(5), pp.1201-1205. DOI: 10.1007/s11136-018-2071-5.	10	1.198	N/A
3	Drummond, M. and <b>Towse, A.</b> , 2019. Is rate of return pricing a useful approach when value-based pricing is not appropriate? <i>A. Eur J Health Econ</i> (2019) 20: 945. <a href="https://doi.org/10.1007/s10198-019-01032-7">https://doi.org/10.1007/s10198-019-01032-7</a>	24	1.042	2
4	Li, A., Manohar, P.M., Garcia, D.A., Lyman, G.H. and <b>Steuten, L.M.</b> 2019. Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States. <i>Thrombosis Research</i> , (180), pp. 37-24. DOI: <a href="https://doi.org/10.1016/j.thromres.2019.05.012">https://doi.org/10.1016/j.thromres.2019.05.012</a> .	20	1.487	N/A
5	Lopez-Picado, A., Barrachina, B., Remon, M. and <b>Errea, M.</b> , 2019. Cost benefit analysis of the use of tranexamic acid in total replacement hip surgery. <i>Journal of Clinical Anesthesia</i> . Vol. 57 (in progress. November 2019), pp. 124-128.	17	1.019	N/A
6	Mewes, J.C., Pulia, M.S., Mansour, M.K., Broyles, M.R., Nguyen, B. and <b>Steuten, L.</b> , 2019. The cost impact of PCT-guided antibiotic stewardship versus usual care for hospitalised patients with suspected sepsis or lower respiratory tract infections in the US: A health economic model analysis. <i>PLOS ONE</i> . DOI: <a href="https://doi.org/10.1371/journal.pone.0214222">https://doi.org/10.1371/journal.pone.0214222</a> .	30	0.885	N/A
7	Murad, Z., Stavropoulou, C., and <b>Cookson, G.</b> 2019. Incentives and gender in a multi-task setting: An experimental study with real-effort tasks, <i>PLOS ONE</i> , 14(3), e0213080. DOI: <a href="https://doi.org/10.1371/journal.pone.0213080">https://doi.org/10.1371/journal.pone.0213080</a> .	10	0.885	N/A
8	Sanchez-Iriso, E., <b>Errea, M.</b> , Cabases, J.M., 2019. Valuing Health using EQ-5D: The impact of chronic diseases on the stock of health. <i>Health Economics</i> . DOI: <a href="https://doi.org/10.1002/hec.3952">https://doi.org/10.1002/hec.3952</a>	6	1.032	3
9	<b>Sampson, C.J.</b> , Arnold R., Bryan, S., Clarke, P., Ekins, S., Hatswell, A., Hawkins, N., Langham, S., Marshall, D., Sadatsafavi, M., Sullivan, W., Wilson, E.C.F., and Wrightson, T. (2019) Transparency in decision modelling: what, why, who and how? <i>PharmacoEconomics</i> . DOI: <a href="https://doi.org/10.1007/s40273-019-00819-z">10.1007/s40273-019-00819-z</a> .	43	1.389	2
10	<b>Steuten, L.</b> , Garmo, V., Phatak, H., Sullivan, S.D., Ngeim, P. and Ramsey, S.D. 2019. Treatment patterns, overall survival, and total healthcare costs of advanced Merkle cell carcinoma in the USA. <i>Applied Health Economics and Health Policy</i> , pp. 1-8. DOI: <a href="https://doi.org/10.1007/s40258-019-00492-5">https://doi.org/10.1007/s40258-019-00492-5</a> .	9	1.017	N/A

11	<b>Steuten, L.</b> , Goulart, B., Meropol, N.J., Pritchard, D. and Ramsey, S.D. 2019. Cost effectiveness of multigene panel sequencing for patients with advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , (3), pp. 1-10. DOI: 10.1200/CCI.19.00002.	54	10.163	N/A
12	<b>Zamora, B.</b> , Gurupira, M., <b>Rhodés Sánchez, M.</b> , Feng, Y., Hernandez-Villafuerte, K., Brown, J. and Shah, K., 2019. The value of international volunteers experience to the NHS. <i>Globalization and Health</i> , 15(31). DOI: <a href="https://doi.org/10.1186/s12992-019-0473-y">https://doi.org/10.1186/s12992-019-0473-y</a> .	9	2.587	N/A
13	<b>Zamora, B.</b> , Maignen, F., <b>O'Neill, P.</b> , Mestre-Ferrandiz, J. and <b>Garau, M.</b> , 2019. Comparing access to orphan medicinal products in Europe. <i>Orphanet Journal of Rare Diseases</i> , 14(1), pp.95.	73	1.120	N/A
14	<b>Davillas, A.</b> and Pudney, S. (2019) Biomarkers as precursors of disability. <i>Economics &amp; Human Biology</i> Available online 10 September 2019, 100814. <a href="https://www.sciencedirect.com/science/article/pii/S1570677X18300959?via%3Dihub">https://www.sciencedirect.com/science/article/pii/S1570677X18300959?via%3Dihub</a>	15	1.041	2
15	Wurcel, V., Cicchetti, A., Garrison, L., Kip, M.M., Koffijberg, H., Kolbe, A., Leeflang, M.M., Merlin, T., Mestre-Ferrandiz, J., Oortwijn, W. and Oosterwijk, C., Tunis, S., <b>Zamora, B.</b> 2019. The Value of Diagnostic Information in Personalised Healthcare: A Comprehensive Concept to Facilitate Bringing This Technology into Healthcare Systems. <i>Public Health Genomics</i> , pp.1-8.	56	0.512	N/A
16	<b>Mott, D.J.</b> , <b>Hampson, G.</b> , Llewelyn, M., Mestre-Ferrandiz, J. and Hopkins, M.M. A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance. <i>Applied Health Economics and Health Policy</i> . doi: <a href="https://doi.org/10.1007/s40258-019-00516-0">10.1007/s40258-019-00516-0</a>	7	1.017	N/A
17	Hilari, K., Behn, N., Marshall, J., Simpson, A., Thomas, S., Northcott, S., Flood, C., McVicker, S., <b>Jofre-Bonet, M.</b> , Moss, B., James, K. and Goldsmith, K., 2019. Adjustment with aphasia after stroke: study protocol for a pilot feasibility randomised controlled trial for Supporting wellbeing through PEEr Befriending (SUPERB). <i>Pilot and Feasibility Studies</i> , 5(1), p.14.	31	N/A	N/A
18	Kuper, H., Lyra, T.M., Moreira, M.E.L., de Albuquerque, M. do S.V., de Araújo, T.V.B., Fernandes, S., <b>Jofre-Bonet, M.</b> , Larson, H., Lopes de Melo, A.P., Mendes, C.H.F., Moreira, M.C.N., do Nascimento, M.A.F., Penn-Kekana, L., Pimentel, C., Pinto, M., Simas, C. and Valongueiro, S., 2019. Social and economic impacts of congenital Zika syndrome in Brazil: Study protocol and rationale for a mixed-methods study. <i>Wellcome Open Research</i> , 3, p.127	36	N/A	N/A
21	Carrieri, V., <b>Davillas, A.</b> , Jones, A.M. (2019). A latent class approach to inequity in health using biomarker data. Health, Econometrics and Data Group (HEDG) Working Papers 19/22, HEDG, c/o Department of Economics, University of York.	19	N/A	N/A
22	Garrison L and <b>Towse A.</b> (2019) A Strategy to Support Efficient Development and Use of Innovations in Personalized Medicine and Precision Medicine. <i>Journal of Managed Care and Speciality Pharmacy</i> . 2019;25(10):1082-87	21	N/A	N/A

23	Pearson SD, Segel C, <b>Cole A</b> , Henshall C, and <b>Towse A</b> . 2019. Policy perspectives on alternative models for pharmaceutical rebates: a report from the Institute for Clinical and Economic Review Policy Summit. Journal of Comparative Effectiveness Research 10.2217/cer-2019-0094 C	4	N/A	N/A
23	<b>Towse A.</b> , and Fenwick E. (2019) Uncertainty and Cures: Discontinuation, Irreversibility, and Outcomes-Based Payments: What Is Different About a One-Off Treatment? Value in Health. 2019; 22(6):677–683.	36	1.414	N/A
2018				
1	Barry, L., Hobbins, A., Kelleher, D., <b>Shah, K., Devlin, N.</b> , Ramos Goñi, J.M. and O'Neill, C., 2018. Euthanasia, Religiosity and the Valuation of Health States: Results from an Irish EQ5D5L Valuation Study and their Implications for Anchor Values. <i>Health and Quality of Life Outcomes</i> , 16(152). DOI: <a href="https://doi.org/10.1186/s12955-018-0985-9">https://doi.org/10.1186/s12955-018-0985-9</a>	12	0.993	N/A
2	Bottomley, A., Pe, M., Sloan, J., Basch, E., Bonnetain, F., Calvert, M., Campbell, A., Cleeland, C., Cocks, K., Collette, L., Dueck, A.C., <b>Devlin, N.</b> , et al. 2018. Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials. <i>Clinical Trials</i> , p.1740774518795637. DOI: <a href="https://doi.org/10.1177/1740774518795637">https://doi.org/10.1177/1740774518795637</a>	48	0.981	N/A
3	<b>Cole, A., Shah, K.</b> , Mulhern, B., <b>Feng, Y.</b> and <b>Devlin, N.</b> , 2018. Valuing EQ-5D-5L Health States 'In Context' Using a Discrete Choice Experiment. <i>European Journal of Health Economics</i> , 19(4), pp.595-605. DOI: <a href="https://doi.org/10.1007/s10198-017-0905-7">https://doi.org/10.1007/s10198-017-0905-7</a>	12	1.042	2
4	<b>Cubí-Mollá, P., Shah, K.K.</b> and Burström, K., 2018. Experience-based Values: A Framework for Classifying Different Types of Experience in Health Valuation Research. <i>The Patient</i> , 11(3), pp.253-270. DOI: <a href="https://doi.org/10.1007/s40271-017-0292-2">https://doi.org/10.1007/s40271-017-0292-2</a>	24	N/A	N/A
5	Danzon, P., Drummond, M., <b>Towse, A.</b> and Pauly, M., 2018. Objectives, Budgets, Thresholds, and Opportunity Costs—A Health Economics Approach: An ISPOR Special Task Force Report. <i>Value in Health</i> , 21(2), pp.140-145. DOI: <a href="https://doi.org/10.1016/j.jval.2017.12.008">https://doi.org/10.1016/j.jval.2017.12.008</a>	61	1.414	N/A
6	<b>Devlin, N.</b> , Brazier, J., Pickard, S.A. and Stolk, E., 2018. 3L, 5L, What the L? A NICE Conundrum. <i>Pharmacoeconomics</i> , 36(6), pp.637-640. DOI: <a href="https://doi.org/10.1007/s40273-018-0622-9">https://doi.org/10.1007/s40273-018-0622-9</a>	27	1.389	2
7	<b>Devlin, N., Shah, K., Feng, Y.</b> , Mulhern, B. and van Hout, B., 2018. Valuing Health-related Quality of Life: An EQ-5D-5L Value Set for England. <i>Health Economics</i> , 27(1)), pp.7-22. <a href="https://doi.org/10.1002/hec.3564">https://doi.org/10.1002/hec.3564</a>	1178	1.032	3
8	<b>Devlin, N.J., Shah, K.K.</b> , Mulhern, B.J., Pantiri, K. and van Hout, B., 2018. A New Method for Valuing Health: Directly Eliciting Personal Utility Functions. <i>European Journal of Health Economics</i> . DOI: <a href="https://doi.org/10.1007/s10198-018-0993-z">https://doi.org/10.1007/s10198-018-0993-z</a>	33	1.042	2

9	<b>Feng, Y., Devlin, N., Shah, K.,</b> Mulhern, B. and van Hout, B., 2018. New Methods for Modelling EQ-5D-5L Value Sets: An Application to English Data. <i>Health Economics</i> , 27(1), pp.7-22. DOI: <a href="http://dx.doi.org/10.1002/hec.3560">http://dx.doi.org/10.1002/hec.3560</a>	80	1.032	3
10	<b>Feng, Y.,</b> Hole, AR., Karimi, M., Tsuchiya, A., and van Hout, B., 2018. An Exploration of the Non-iterative Time Trade-off Method to Value Health States. <i>Health Economics</i> , 27(8), pp.1247-1263. DOI: <a href="https://doi.org/10.1002/hec.3773">https://doi.org/10.1002/hec.3773</a>	3	1.032	3
11	<b>Garau, M., Hampson, G., Devlin, N.,</b> Amedeo, N., Amedeo Mazzanti, N., Profico, A., 2018. Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders' Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL). <i>Pharmacoeconomics Open</i> , 2(2), pp.153-163. DOI: <a href="https://doi.org/10.1007/s41669-017-0048-x">https://doi.org/10.1007/s41669-017-0048-x</a>	33	0.646	N/A
12	Garrison, L.P., Neumann, P.J., Wilkie, R.J., Basu, A., Danzon, P.M., Doshi, J.A., Drummond, M.F., Lakdawalla, D.N., Pauly, M.V., Phelps, C.E., <b>Towse, A.</b> and Weinstein, M.C., 2018. A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report [7]. <i>Value in Health</i> , 21(2), pp.161-165. DOI: <a href="https://doi.org/10.1016/j.jval.2017.12.009">https://doi.org/10.1016/j.jval.2017.12.009</a>	146	1.414	N/A
13	<b>Hampson, G., Towse, A.,</b> Pearson, S., Dreitlein, W., Henshall, C., 2018. Gene Therapy: Evidence, Value and Affordability in the US Health Care System. <i>Journal of Comparative Effectiveness Research</i> , 7(1), pp.15-28. DOI: <a href="https://doi.org/10.2217/ceer-2017-0068">https://doi.org/10.2217/ceer-2017-0068</a>	119	0.575	N/A
14	Hernandez-Villafuerte, K., Fischer, A., and Latimer, N. 2018. Challenges and Methodologies in Using Progression Free Survival as a Surrogate for Overall Survival in Oncology. <i>International Journal of Technology Assessment in Health Care</i> , 34(3), pp.300-316. DOI: <a href="https://doi.org/10.1017/S0266462318000338">https://doi.org/10.1017/S0266462318000338</a>	16	0.849	N/A
15	Hobbins, A., Barry, L., Kelleher, D., <b>Shah, K., Devlin, N.,</b> Ramos Goñi, J.M. and O'Neill, C., 2018. Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L. <i>Pharmacoeconomics</i> . DOI: <a href="https://doi.org/10.1007/s40273-018-0690-x">https://doi.org/10.1007/s40273-018-0690-x</a>	76	1.389	2
16	Hoque, D.E., Ruseckaite, R., <b>Lorgelly, P.,</b> McNeil, J.J. and Evans, S.M., 2018. Cross-sectional Study of Characteristics of Clinical Registries in Australia: A Resource for Clinicians and Policy Makers. <i>International Journal for Quality in Health Care</i> , 30(3), pp.192-199. DOI: <a href="https://doi.org/10.1093/intqhc/mzx196">https://doi.org/10.1093/intqhc/mzx196</a>	23	0.741	1
17	Jonsson, B., <b>Hampson, G.,</b> Michaels, J., <b>Towse, A.,</b> Graf von der Schulenburg, J.M. and Wong, O. 2018. Advanced Therapy Medicinal Products and Health Technology Assessment Principles and Practices for Value-based and Sustainable Healthcare, <i>The European Journal of Health Economics</i> , DOI: <a href="https://doi.org/10.1007/s10198-018-1007-x">https://doi.org/10.1007/s10198-018-1007-x</a>	106	1.042	2
18	Karlsberg-Schaffer, S., Messner, D., Mestre-Ferrandiz, J., Tambor, E. and <b>Towse, A.,</b> 2018. Paying for Cures: Perspectives on Solutions to the "Affordability Issue". <i>Value in Health</i> , 21(3), pp.76-279. DOI: <a href="https://doi.org/10.1016/j.jval.2017.12.013">https://doi.org/10.1016/j.jval.2017.12.013</a>	42	1.414	N/A

19	Kreimeier, S., Oppe, M., Ramos-Goñi, J.M., <b>Cole, A., Devlin, N.J.</b> , Herdman, M., Mulhern, B., <b>Shah, K.K.</b> , Stolk, E., Rivero-Arias, O. and Greiner, W., 2015. Valuation of EuroQol Five-dimensional Questionnaire, Youth Version (EQ5D-Y) and EuroQol Five-dimensional Questionnaire, Three-level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective. <i>Value in Health</i> . DOI: <a href="https://doi.org/10.1016/j.jval.2018.05.002">https://doi.org/10.1016/j.jval.2018.05.002</a>	76	1.414	N/A
20	<b>Lorgelly, P.K.</b> , 2018. The Impact of Brexit on Pharmaceuticals and HTA. <i>Pharmacoeconomics Open</i> , 2 (2), pp. 87-91. DOI: <a href="https://doi.org/10.1007/s41669-018-0072-5">https://doi.org/10.1007/s41669-018-0072-5</a>	3	N/A	N/A
21	<b>Lorgelly, P.K.</b> , and <b>Neri, M.</b> , 2018. Survivorship Burden for Individuals, Households and Society: Estimates and Methodology. <i>Journal of Cancer Policy</i> , DOI: <a href="https://doi.org/10.1016/j.jcpc.2018.02.005">https://doi.org/10.1016/j.jcpc.2018.02.005</a>	28	N/A	N/A
22	<b>Mott, D.J.</b> , 2018. Incorporating Quantitative Patient Preference Data into Healthcare Decision Making Processes: Is HTA Falling Behind? <i>Patient</i> , DOI: <a href="https://doi.org/10.1007/s40271-018-0305-9">https://doi.org/10.1007/s40271-018-0305-9</a>	51	N/A	N/A
23	Mulhern, B., <b>Feng, Y., Shah, K.</b> , Janssen, M.F., Herdman, M., van Hout, B. and <b>Devlin, N.</b> , 2018. Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets. <i>Pharmacoeconomics</i> , DOI: <a href="https://doi.org/10.1007/s40273-018-0628-3">https://doi.org/10.1007/s40273-018-0628-3</a>	893	1.389	2
24	Mulhern, B., Norman, R., <b>Shah, K.</b> , Bansback, N., Longworth, L. and Viney, R., 2018. How Should DCE with Duration Choice Sets be Presented for the Valuation of Health States? <i>Medical Decision Making</i> , 38(3), pp.306-318, DOI: <a href="http://doi.org/10.1177/0272989X17738754">http://doi.org/10.1177/0272989X17738754</a>	10	1.263	N/A
25	Pe, M., Dorme, L., Coens, C., Basch, E., Calvert, M., Campbell, A., Cleeland, C., Cocks, K., Collette, L., Dirven, L., Dueck, A.C., <b>Devlin, N.</b> , et al., 2018. Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review. <i>The Lancet Oncology</i> , 19(9), pp.e459-e469. DOI: <a href="https://doi.org/10.1016/S1470-2045(18)30418-2">https://doi.org/10.1016/S1470-2045(18)30418-2</a>	72	12.270	N/A
26	Phelps, C.E., Lakdawalla, D.N., Basu, A., Drummond, M.F., <b>Towse, A.</b> and Danzon, P.M. 2018, Approaches to Aggregation and Decision Making—A Health Economics Approach: An ISPOR Special Task Force Report [5] <i>Value in Health</i> , 21(2), pp.146-154. DOI: <a href="https://doi.org/10.1016/j.jval.2017.12.010">https://doi.org/10.1016/j.jval.2017.12.010</a>	71	1.414	N/A
27	Russell, D., Atkin, L., Betts, A., Dowsett, C., Fatoye, F., Gardner, S., Green, J., Manu, C., McKenzie, T., Meally, H., Mitchell, L., Mullings, J., Odeyimi, I., Sharpe, A., Yeowell, G. and <b>Devlin, N.</b> , 2018. Using a modified Delphi methodology to gain consensus on the use of dressings in chronic wounds management. <i>Journal of Wound Care</i> , 27(3), pp.156-165. DOI: <a href="https://doi.org/10.12968/jowc.2018.27.3.156">https://doi.org/10.12968/jowc.2018.27.3.156</a>	14	0.459	N/A
28	<b>Shah, K.K.</b> , Tsuchiya, A. and Wailoo, A.J., 2018. Valuing Health at the End-of-Life: A Review of Stated Preference Studies in the Social Sciences Literature. <i>Social Science &amp; Medicine</i> , 204, pp.39-50, DOI: <a href="https://doi.org/10.1016/j.socscimed.2018.03.010">https://doi.org/10.1016/j.socscimed.2018.03.010</a>	32	1.978	N/A
29	Shen, J., Hill, S., <b>Mott, D.</b> , Breckons, M., Vale, L., and Pickard, R. 2018. Conducting a Time Trade-Off Study Alongside a Clinical Trial: A Case Study and Recommendations. <i>Pharmacoeconomics Open</i> . DOI: <a href="https://doi.org/10.1007/s41669-018-0084-1">10.1007/s41669-018-0084-1</a>	10	0.646	N/A

30	<b>Towse, A.</b> and Mauskopf. 2018, Affordability of New Technologies: The Next Frontier, <i>Value in Health</i> . DOI: <a href="https://doi.org/10.1016/j.jval.2018.01.011">https://doi.org/10.1016/j.jval.2018.01.011</a>	31	1.414	N/A
31	Wong, E.L., <b>Shah, K.</b> , Cheung, A.W.L., Wong, A.Y.K., Visser, M. and Stolk, E., 2018. Evaluation of Split Version and Feedback Module on the Improvement of Time Trade-off Data. <i>Value in Health</i> , 21, pp.732-741, DOI: <a href="https://doi.org/10.1016/j.jval.2017.10.013">https://doi.org/10.1016/j.jval.2017.10.013</a>	12	1414	N/A
32	Yang, F., <b>Devlin, N.</b> and Luo, N., 2018. Impact of mapped EQ-5D utilities on cost-effectiveness analysis: in the case of dialysis treatments. <i>The European Journal of Health Economics</i> , pp.1-7. DOI: <a href="https://doi.org/10.1007/s10198-018-0987-x">https://doi.org/10.1007/s10198-018-0987-x</a>	14	1.042	2
33	Yang, F., Devlin, N. and Luo, N., 2018. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter? <i>Value in Health</i> . DOI: <a href="https://doi.org/10.1016/j.jval.2018.05.008">https://doi.org/10.1016/j.jval.2018.05.008</a>	35	1.414	N/A
34	<b>Zamora, B.</b> and <b>Garau, M.</b> 2018. Policymakers Should Do More to Ensure Timely Access to Orphan Medicinal Products. <i>The Government Gazette</i> , 2, pp. 36.	N/A	N/A	N/A

- 1 Google Scholar. The number of citations for each article as of October 2023
- 2 SCImago Journal Rank (SJR) indicator (PDF), developed by SCImago from the widely known algorithm Google PageRank™. This indicator shows the visibility of the journals contained in the Scopus® database from 1996. SJR takes into account both the number of citations received by a journal and the prestige of the journal based on where those citations come from. The latest available year of indicators is 2022.
- 3 Chartered Association of Business Schools (ABS), UK: journal rankings go from 4\* (highest) to 1 (lowest). The latest available year of rankings is 2021.

**About us**

Founded in 1962 by the Association of the British Pharmaceutical Society, the Office of Health Economics (OHE) is not only the world's oldest health economics research group, but also one of the most prestigious and influential.

OHE provides market-leading insights and in-depth analyses into health economics & health policy. Our pioneering work informs health care and pharmaceutical decision-making across the globe, enabling clients to think differently and to find alternative solutions to the industry's most complex problems.

Our mission is to guide and inform the healthcare industry through today's era of unprecedented change and evolution. We are dedicated to helping policy makers and the pharmaceutical industry make better decisions that ultimately benefit patients, the industry and society as a whole.

*OHE. For better healthcare decisions.*

**Areas of expertise**

- Evaluation of health care policy
- The economics of health care systems
- Health technology assessment (HTA) methodology and approaches
- HTA's impact on decision making, health care spending and the delivery of care
- Pricing and reimbursement for biologics and pharmaceuticals, including value-based pricing, risk sharing and biosimilars market competition
- The costs of treating, or failing to treat, specific diseases and conditions
- Drivers of, and incentives for, the uptake of pharmaceuticals and prescription medicines
- Competition and incentives for improving the quality and efficiency of health care
- Incentives, disincentives, regulation and the costs of R&D for pharmaceuticals and innovation in medicine
- Capturing preferences using patient-reported outcomes measures (PROMs) and time trade-off (TTO) methodology
- Roles of the private and charity sectors in health care and research
- Health and health care statistics